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this paradigm by demonstrating that TLRs are also expressed on T lymphocytes and that TLR ligands can
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differentiation protein 88 (MyD88), have increased susceptibility to numerous pathogens, highlighting the
importance of TLRs in host defense. While the immune impairments associated with MyD88-deficiency
have generally been attributed to the importance of MyD88 in regulating innate immune responses, in
light of the studies showing that TLRs can directly stimulate T cells, we hypothesized that they may also
reflect a direct role for MyD88 in T cells. In this work, we use lymphocytic choriomeningitis virus (LCMV)
as a model infection to examine the role of MyD88 in regulating antiviral T cell responses. Using a series
of adoptive cell transfer and bone marrow chimera experiments, we identify a critical, but previously
unappreciated, T-cell intrinsic role for MyD88 in regulating the survival and expansion of LCMV-specific
effector T cells during acute viral infection. Using a system to inducibly delete MyD88 we also show that,
while naïve T cells critically depend on MyD88-dependent signals for their expansion, virus-specific
memory T cells do not require MyD88 for their differentiation, maintenance or reactivation in response to
secondary infection. Overall, our findings broaden the importance of MyD88 in T cells, support a shift in
the dogma that restricts the role MyD88 to cells of the innate immune system, and may have significant
implications for understanding the signals that control T cell survival during inflammatory immune
responses.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Immunology

First Advisor
Laurence Turka

Keywords
T cell, toll-like receptor, survival, expansion, virus

Subject Categories
Immunity

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/37

DEFINING A T CELL-INTRINSIC ROLE FOR
MYD88 DURING LCMV INFECTION
Adeeb Habibur Rahman
A DISSERTATION
in
Immunology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2009

______________________________________
Laurence A. Turka, M.D., Dissertation Advisor
______________________________________
Steven Reiner, M.D., Graduate Group Chair
Dissertation Committee:
Terri Laufer, M.D.
E. John Wherry, Ph.D.
Christopher Hunter, Ph.D.
Hao Shen, Ph.D.

ACKNOWLEDGEMENTS
This dissertation would not have been possible without the help and support of numerous
people. I offer my deepest gratitude:
First and foremost, to Larry, for providing me with unrestrained funding and space, astute
experimental and editorial advice, freedom to pursue my own ideas, and assistance in
innumerable other ways throughout the course of my time in his lab.
To my collaborators, John Wherry, Hao Shen, Susan Kaech, Weiguo Cui, Haina Shin,
Erika Pearce, Allison Crawford and Joanna Dispirito for reagents, help with experimental
design and teaching me the ins and outs of LCMV.
To my committee members for their insightful comments, criticisms and suggestions and
for generally making committee meetings an enjoyable experience.
To all my lab mates, both past and present, for their scientific input and their
camaraderie. In particular, to Andy Gelman, Dave LaRosa and Devon Taylor for their
mentorship when I first joined the lab, and to my bay-mates Paige Porrett and Scott
Lieberman for tolerating my mess, providing entertaining distractions and constantly
making lab a more fun place to be.
To the Immunology Graduate Group, particularly Jon Malztman, Avinash Bhandoola,
Andrew Wells, John Monroe, Mike Cancro and Steve Reiner for their advice and
assistance throughout my time in graduate school and my fellow classmates for their
general awesomeness.
To the Flow Cytometry Core, including Hank Pletcher, Bill Murphy and Ryan
Wychowanec for performing countless hours of cell sorting, teaching me how to use the
cytomters and cell sorter and accommodating my weird schedule.
To Gina, Rob, Troy, Jamal, Paula, Yvonne, Yolanda, Christine, Abigail and all the other
ULAR staff who helped me keep my mice alive, well and breeding.
To Donald Jackson and George Yap for being fantastic undergraduate mentors and
motivating me to go to graduate school.
And last, but mostly certainly not least, my family and friends, especially my parents for
their love and support and my incredible wife for being inexplicably accepting of my
crazy work hours and giving me the motivation to get this thing done.

ii

ABSTRACT
DEFINING A T CELL-INTRINSIC ROLE FOR MYD88 DURING LCMV
INFECTION
Adeeb Habibur Rahman
Laurence Turka, M.D.

Immune activation through Toll-like receptors (TLRs) has historically been considered to
be a characteristic of cells of the innate, rather than adaptive immune system. Recent
studies have challenged this paradigm by demonstrating that TLRs are also expressed on
T lymphocytes and that TLR ligands can directly co-stimulate T cell responses in vitro.
However, the physiological relevance of these findings during in vivo immune responses
was unclear. Mice lacking the critical TLR-adapter protein, myeloid differentiation
protein 88 (MyD88), have increased susceptibility to numerous pathogens, highlighting
the importance of TLRs in host defense. While the immune impairments associated with
MyD88-deficiency have generally been attributed to the importance of MyD88 in
regulating innate immune responses, in light of the studies showing that TLRs can
directly stimulate T cells, we hypothesized that they may also reflect a direct role for
MyD88 in T cells. In this work, we use lymphocytic choriomeningitis virus (LCMV) as a
model infection to examine the role of MyD88 in regulating antiviral T cell responses.
Using a series of adoptive cell transfer and bone marrow chimera experiments, we
identify a critical, but previously unappreciated, T-cell intrinsic role for MyD88 in
iii

regulating the survival and expansion of LCMV-specific effector T cells during acute
viral infection. Using a system to inducibly delete MyD88 we also show that, while naïve
T cells critically depend on MyD88-dependent signals for their expansion, virus-specific
memory T cells do not require MyD88 for their differentiation, maintenance or
reactivation in response to secondary infection. Overall, our findings broaden the
importance of MyD88 in T cells, support a shift in the dogma that restricts the role
MyD88 to cells of the innate immune system, and may have significant implications for
understanding the signals that control T cell survival during inflammatory immune
responses.
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CHAPTER I: Introduction and Overview

Introduction
The immune system can broadly be divided into two arms: the innate and adaptive. The
innate immune system serves as a first line of defense against pathogens and also plays
an important role in initiating and directing adaptive immune responses. Cells of the
innate immune system, such as neutrophils, macrophages and dendritic cells, recognize
foreign antigens through a limited range of germ-line encoded receptors, collectively
known as pattern recognition receptors (PRRs)(Janeway & Medzhitov 2002). These PRRs
recognize highly conserved molecular motifs that are generally found in microbial
pathogens, but not in their eukaryotic hosts and are thus termed pathogen-associated
molecular patterns (PAMPs). In contrast, cells of the adaptive immune system, such as B
and T lymphocytes are activated through antigen receptors that are generated by genetic
rearrangement and selected to recognize an incredibly diverse array of potential
ligands(Oettinger et al. 1990). Thus, activation through PRRs, versus rearranged antigen
receptors, has historically been considered a defining feature that distinguishes cells of
the innate arm from those of the adaptive arm of the immune system.

Toll like receptors
Several classes of PRRs have been now described, but Toll like receptors (TLRs)
represent one of the best characterized. TLRs are a family of evolutionarily conserved
receptors that have a broad, heterogeneous tissue expression pattern, and whose ligands
1

can mediate effects on a variety of cell types. The TLR family currently includes at least
11 members that bind to a range of microbial components from bacteria, fungi and
viruses. TLRs 2, 4, 5 and 11 are expressed on the cell surface and recognize bacterial
lipoproteins, lipopolysaccharide (LPS), flagellin and profilin respectively. TLRs 3, 7, 8
and 9 are expressed in endosomal compartments and are involved in the recognition of
double stranded RNA, single stranded RNA, and unmethylated CpG DNA, respectively.
These details of TLR ligand-recognition and cellular localization are summarized in
Table 1. The molecular mechanisms that allow for the broad diversity in TLR ligand
recognition remain unclear and recent studies of the structure of TLR receptor-ligand
complexes suggest that different TLRs may employ different ligand-binding interfaces(Jin
et al. 2007)(H. M. Kim et al. 2007)(L. Liu et al. 2008).

While TLRs have generally been considered a means to distinguish “non-self”
from “self”, it is interesting to note that endogenous molecules may also act as TLR
ligands. In analogy to PAMPs, these putative endogenous ligands may be considered
damage associated molecular patterns (DAMPs)(Bianchi 2007). Heat shock proteins
(HSPs), and extracellular matrix components such as fibronectin and hyaluronan are
released during stressful tissue injury and have been reported to activate the innate
immune system through TLR2 and TLR4(Vabulas et al. 2001)(Ohashi et al. 2000)(Okamura
et al. 2001)(Termeer et al. 2002), though the potential contamination of these endogenous

ligands with PAMPs is a concern in some of these studies(Gao & Tsan 2003a)(Gao & Tsan
2003b). In addition, chromatin complexes released from damaged cells contain nucleic

acids that can engage TLR7 and TLR9(Leadbetter et al. 2002)(Lau et al. 2005). Indeed, it
2

has been suggested that the intracellular localization of these nucleic acid-sensing TLRs
restricts their access of to endogenous ligands and thereby contributes to the
discrimination between self and non-self nucleic acids(Barton et al. 2006). However, this
discrimination is imperfect and, consequently, TLR-mediated recognition of endogenous
nucleoproteins has been implicated in the development and progression of autoimmune
diseases such systemic lupus erythamtosis (SLE)(Christensen et al. 2006)(Ehlers et al. 2006).
These studies highlight the fact that the TLR family plays a role in the recognition of an
incredibly broad array of ligands, the overall diversity of which may yet to be fully
appreciated.

TLR signaling
TLRs are type I integral membrane glycoproteins that contain a leucine rich repeat motif,
which serves as a ligand binding domain, and an intracellular cytoplasmic
Toll/interleukin-1 receptor (TIR) domain that initiates signal transduction(Jin et al.
2007)(Jin & Lee 2008). The super-family of TIR-domain containing receptors also includes

the IL-1R/IL-18R family(Adachi et al. 1998). These receptors act by recruiting and
homodimerizing with TIR domain-containing adaptors proteins. Myeloid differentiation
protein 88 (MyD88) is one of several adapter proteins linking these receptors to
downstream signaling molecules(Medzhitov et al. 1998). Importantly, MyD88 is required
for signaling through all TLRs except TLR3, which signals through the alternate adaptor
molecule, Toll/IL-1R domain containing adaptor-inducing IFN- (TRIF), and TLR4,
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which can signal through both MyD88- and TRIF-dependent pathways(Yamamoto et al.
2002)(Yamamoto et al. 2003).

Following interaction with upstream receptors through its TIR domain, MyD88
recruits downstream signaling molecules through its death domain. Homotypic deathdomain interactions lead to the activation of IL-1 receptor-associated kinases (IRAKs)
and the subsequent activation of TNF receptor-associated factor 6 (TRAF6), ultimately
resulting in the activation of NFB and AP-1(Wesche et al. 1997)(Martin & Wesche 2002).
While the nuclear translocation of NFB is generally considered to be classical outcome
of MyD88-dependent signaling pathways, numerous studies have established that there is
considerably more diversity and complexity in the potential signaling pathways that can
be induced through MyD88. For example, TLR signaling can also activate the Akt
pathway through a direct interaction of phosphatidylinositol 3-kinase (PI-3-K) with a
tyrosine motif in the MyD88 TIR domain(Li et al. 2003)(Rhee et al. 2006)(Gelman et al.
2006). MyD88 has also been shown to form complexes with interferon regulatory factors

(IRF)-1, IRF-5, and IRF-7, which play an important role in the induction of type I
interferons (IFN-I) and other proinflammatory cytokines by TLR signaling in APCs
(Balkhi et al. 2008a)(Takaoka et al. 2005)(Kawai et al. 2004)(Honda et al. 2005)(Balkhi et al.
2008b)(Honda et al. 2004).

MyD88 has also been found to contribute to pathways outside of its traditional
role in TLR signaling. The ability of MyD88 to undergo homotypic interactions with
other death-domain containing proteins has been shown to allow it to interact with Fasassociated protein with death domain (FADD), implicating MyD88 as a bridge between
4

TLR and Fas-mediated signaling pathways(Altemeier et al. 2007)(Zhande et al. 2007).
Additionally, MyD88 has been shown to be able to interact with the interferon gamma
receptor (IFNR1) and stabilize IFN-induced mRNA transcripts(D. Sun & Ding 2006).
Overall, these studies identify MyD88 as a critical regulator of TLR signaling and an
important branching point in the diversity of signals and cellular outcomes that can be
induced through TLR stimulation and other potential upstream mediators.

TLRs stimulate antigen presenting cell responses
TLRs are highly expressed on antigen presenting cells (APCs) of the innate immune
system, such as macrophages and dendritic cells, and have been most extensively studied
in these cell types. TLR engagement induces APC maturation, characterized by increased
expression of costimulatory molecules such as CD80 and CD86 as well as the production
of pro-inflammatory cytokines such as IL-12, IL-6 and type I IFNs(Fearon & Locksley
1996)(Krug et al. 2001). Furthermore, maturation precipitates a shift in adhesion molecule

and chemokine expression allowing APCs to traffic to the T cell areas of the spleen and
lymph nodes(Michelsen et al. 2001)(Turnbull et al. 2005). TLR engagement also promotes
the stability of cognate MHC peptide complexes and upregulates their expression on the
surface of APCs(Hertz et al. 2001)(Rudd et al. 2008), and the presence of TLR ligands in
phagocytosed antigens has also been shown to promote the generation of peptide:MHC
Class II complexes thereby directly enhancing the presentation of phagocytosed
antigens(Blander & Medzhitov 2006). On account of these effects, TLR stimulation on
APCs allows them to more effectively activate T cells, promoting the proliferation and
5

differentiation of naïve T cells into effector cells. In the absence of these maturation
signals, the ability of APCs to initiate T cell responses is greatly reduced(Pasare &
Medzhitov 2004).

TLRs are expressed on B and T lymphocytes
Due to their importance in the antigen presenting cells, it is well established that TLRs
also play a key, indirect role in promoting adaptive immune responses. However, recent
studies have demonstrated that the expression and function of TLRs is not limited to cells
of the innate immune system. Mouse and human B lymphocytes have been found to
express several TLRs and TLR stimulation promotes B cell proliferation, differentiation,
antibody class switching, cytokine production and survival(Pasare & Medzhitov
2005)(Ruprecht & Lanzavecchia 2006)(Yi et al. 1998). The ability of TLR ligands to modulate

B cell responses demonstrates that TLRs can directly contribute to adaptive immune
responses. A number of studies have now further extended these findings to show that
TLRs are also expressed by various subsets of T lymphocytes.
In two studies, sorted CD4+CD45RBhigh T cells from C57BL/6 (B6) mice were
found to express TLR1, 2, 3, 6, 7 and 8, but low to undetectable levels of TLR 4, 5 and 9
mRNA(Caramalho et al. 2003)(Tomita et al. 2008). Naïve CD4 T cells from BALB/c mice
have been shown to express mRNA for TLR3, 4, 5 and 9(Gelman et al. 2004), while naïve
CD8 T cells from B6 mice have been reported to express mRNA for TLR1, 2, 6 and 9 but
not TLR4(Sobek et al. 2004)(Cottalorda et al. 2006). Regarding protein expression, TLR2, 3,
4 and 9 protein have been reported to be found on murine CD4 T cells via flow
6

cytometry(Fukata et al. 2008), and TLR2 protein has been detected by flow cytometry on
murine CD8 T cells(Sobek et al. 2004)(Cottalorda et al. 2006). Furthermore, human T cells
isolated from peripheral blood have also been reported to express mRNA for most TLRs,
though there is considerable variation in the reported expression levels in these
studies(Hornung et al. 2002)(Mansson et al. 2006)(Zarember & Godowski 2002). Protein
expression of TLR2, 3, 4, 5, 9 has also been detected by flow cytometry on human T
cells(Mansson et al. 2006)(Crellin et al. 2005)(Komai-Koma et al. 2004)(Wesch et al. 2006).
Stimulation through the B cell receptor has been shown to upregulate TLR
expression on B cells, resulting in enhanced sensitivity to TLR ligands(Ruprecht &
Lanzavecchia 2006). Similarly, TLR expression on T cells appears to be regulated by T cell

receptor-dependent activation. Naïve BALB/c CD4 T cells upregulate TLR3 and TLR9
mRNA in response to T cell receptor (TCR) stimulation by CD3 antibodies(Gelman et al.
2004). Furthermore, while naïve BALB/c T cells were shown to express intracellular

TLR2, expression on the cell surface was only readily detectable by flow cytometry
following CD3-induced activation(Liu et al. 2006). Similarly, B6 CTLs express higher
levels of TLR2 mRNA than naïve CD8 T cells(Sobek et al. 2004) and TCR stimulation
increases surface expression of TLR2 protein as detected by flow cytometry(Cottalorda et
al. 2006). Antigen experienced T cells appear to continue to maintain higher levels of TLR

expression since CD4+CD45RBlow memory cells have also been shown to express higher
mRNA levels of most TLRs than naïve CD4+CD45RBhigh T cells(Caramalho et al. 2003)
and human CD45RO+ memory CD4 T cells express higher levels of TLR2 than naïve T
cells(Komai-Koma et al. 2004).
7

To summarize the above, while TLR expression on various T cell subsets has
been independently confirmed by a number of studies, the specific patterns of expression
that have been reported vary considerably. Thus there may be significant species, and
even strain, specific differences in TLR expression. It is also possible that these
differences in expression result from technical variations in different studies. It is also
important to note that mRNA levels do not always correlate with protein expression, and
TLR expression is known to be regulated at the protein level by ubiquitin-mediated
degradation(Chuang & Ulevitch 2004)(Boone et al. 2004). Furthermore, minimal
contamination of purified T cells by APCs could significantly influence results. In
addition, studies that have examined TLR protein levels in T cells are limited by the
reliability of available antibody reagents and personal experience with reagents to detect
murine TLRs via flow cytometry has been quite variable. These caveats may partially
explain the considerable variability in the TLR expression patterns that have been
reported on T cells. Given the limitations in examining expression levels of TLRs on T
cells, the ability of known TLR ligands to activate signaling pathways may be a more
reliable indicator of expression.

TLRs can act as T cell costimulatory receptors
Effective T cell activation requires a primary signal delivered through the TCR, however
this signal alone is insufficient to induce effective T cell activation. Optimal expression
of effector cytokines and the synthesis of pro-survival molecules depend on additional
secondary signals delivered through co-stimulatory receptors. CD28 is generally
8

considered to be the principle co-stimulatory receptor involved in initial T cell
activation(Sharpe & Freeman 2002) and early studies using CD28 deficient T cells found
greatly reduced T cell responses in the absence of CD28 signaling(Lucas et al. 1995). A
number of studies have now found that TLR ligands can act directly on highly purified
 T cells to provide costimulatory signals in the absence of traditional CD28 signaling
from APCs.
Conventional CD4 and CD8 T cells
As discussed earlier, mouse and human CD4 and CD8 T cells have been shown to
upregulate TLR2 expression as a result of activation through the TCR(Komai-Koma et al.
2004)(Cottalorda et al. 2006). Consistent with the this increased expression, it has been

demonstrated that the synthetic TLR2 ligand, Pam3CysSK4, can act directly on highly
purified B6 CD8 T cells to promote enhanced proliferation and survival associated with
sustained CD25 expression(Cottalorda et al. 2006). TLR2 ligands also promote CD8 T cell
effector functions such as IFN production, granzyme B secretion and cytolytic activity.
Costimulation through TLR2 also allows lowers the threshold of activation, thereby
allowing CD8 T cells to differentiate into functional memory cells in response suboptimal
levels of TCR stimulation(Mercier et al. 2009). TLR2 has similarly been shown to
costimulate proliferation and IFN production from B6 mouse CD4 T cells(Rahman et al.
2009). While purified CD4 T cells from Balb/c mice were reported to not respond to

TLR2, 5 or 7 ligands, Poly(I:C) and CpG-containing oligonucleotides (CpG-ODN), the
synthetic ligands for TLR3 and TLR9 respectively, promoted enhanced activated T cell
survival(Gelman et al. 2004). CpG-ODN have also been shown to support enhanced
9

proliferation and IL-2 production from activated B6 CD4 T cells(Gelman et al.
2006)(Bendigs et al. 1999) and have recently also been shown to enhance proliferation of

rat CD4 T cells(Chiffoleau et al. 2007).
Similarly to mouse T cells, both naïve CD45RA+ and memory CD45RO+ human
CD4 T cells have been shown to directly respond to TLR2 ligands(Komai-Koma et al.
2004). However, in contrast to mouse T cells, synthetic ligands for TLR5 and 7/8 have

also been shown to enhance proliferation and cytokine production in human CD4 T cells,
particularly in CD45RO+ memory cells(Caron et al. 2005). A recent study has also found
that human, but not mouse, CD8 T cells produce IFN, perforin and granzyme in
response to LPS signaling through TLR4(Komai-Koma et al. 2009). In contrast, another
recent study attributes to the costimulatory effect of LPS on human CD4 T cells to APC
contamination, but supports a role for direct TLR2 and TLR5 induced signals in
promoting cytokine production and reducing the threshold for CD4 T cell
activation(Lancioni et al. 2009). Notably, this study highlights the importance of stringent T
cell purification methods when studying the direct effects of TLR ligands on T cells since
minimal APC contamination is sufficient to significantly alter the results of experiments.
Overall, these studies demonstrate that several TLR ligands can act directly on T
cells in vitro, though there are clearly species, and even strain specific differences in the
ligands that are recognized. It is important to note that these studies consistently show
that TLR-induced signals in naïve T cells are strictly co-stimulatory, in that TLR ligands
appear to modulate T cell responses induced by TCR signaling but do not appear to
produce functional responses in naïve T cells in the absence of concurrent TCR
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stimulation. This may reflect the importance of preventing TLR signals from inducing
non-specific T cell activation. In contrast, after having been activated through their TCR,
effector and memory T cells appear to maintain responsiveness to TLR ligands in the
absence of concurrent TCR-induced signals(Gelman et al. 2004)(Cottalorda et al. 2009).
Functional responses of TLR9-induced co-stimulation in B6 CD4 T cells can be
attributed to two main signaling pathways mediated by the adaptor molecule, MyD88. As
has been shown in multiple other cell types, stimulation with CpG oligonucleotides
(CPG-ODN) induces MyD88-dependent NF-B activation in CD4 T cells through
homotypic death domain interactions with IRAKs. This NF-B-dependent pathway
upregulates expression of the anti-apoptotic molecule Bcl-xL, and thereby promotes
activated CD4 cell survival(Gelman et al. 2004). TLR2 stimulation has been found to
similarly enhance survival and Bcl-xL expression in activated CD8 T cells(Cottalorda et
al. 2006). While NF-B activation alone appears to be required for CpG-ODN to induce

anti-apoptotic signals in T cells, this pathway synergizes with a PI-3-kinase dependent
pathway in promoting proliferative responses and IL-2 production(Gelman et al. 2006). In
contrast to the death domain interactions by which MyD88 activates NF-B, MyD88dependent PI-3 kinase activation involves a tyrosine residue located in the TIR domain.
This allows MyD88 to associate with the p85 regulatory subunit of PI-3 kinase and
induce Akt phosphorylation in response to TLR stimulation(Gelman et al. 2006). Thus,
specific outcomes of TLR-mediated stimulation in T cells may be associated with
discrete MyD88 motifs and signaling pathways. It will be of interest to determine
whether induction of this PI-3-kinase signaling pathway is specific to TLR9, which is
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expressed intracellularly, or are also shared by other TLRs expressed on the cell surface,
such as TLR2.
Interestingly, stimulation of CD4 T cells with TLR ligands also results in
enhanced expression of secondary co-stimulatory receptors that are generally upregulated
following initial T cell activation(Rahman et al. 2009). Certain co-stimulatory receptors,
such as CD154, play an important role in allowing CD4 T cells to promote B cell
immune responses, which may relate to the finding that MyD88 expression in CD4 T
cells is critical in supporting B cell-class switching to IgG production in an in vivo model
of CpG DNA- induced antibody responses against a T cell dependent antigen(Gelman et
al. 2006). Secondary co-stimulatory receptors can also play an important role in

supporting sustained T cell responses. For example, signals delivered through OX-40
serve to enhance CD4 T cell effector responses, survival and IL-2 production(Gramaglia et
al. 2000). Given that T cell responses induced by these co-stimulatory receptors are quite

similar to those that occur following TLR stimulation it is possible that, in addition to the
direct TLR-induced signaling pathways discussed above, some of the functional
outcomes of TLR stimulation on T cells may reflect secondary consequences of enhanced
signaling through these induced co-stimulatory pathways.
The studies described thus far have focused on survival, proliferation and effector
cytokine production as readouts of functional TLR responses in T cells. However, in
considering other aspects of T cell physiology it has been found that LPS treatment
increased adhesion of mouse and human T cells to fibronectin and inhibited
chemotaxis(Zanin-Zhorov et al. 2007). Human T cells were also reported to respond
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similarly to the endogenous ligand HSP60 through TLR2, though these results could
reflect potential contamination of commercially available HSP60 with bacterial TLR2
ligands(Zanin-Zhorov et al. 2006). These results suggest that, in addition to enhancing T cell
effector functions, TLR signaling in T cells may also play a role in controlling T cell
trafficking. The finding that T cells may potentially respond to endogenous TLR ligands
is particularly intriguing since this presents the possibility that DAMPs may act to recruit
T cells and support their responses at sites of tissue inflammation and necrosis. These
findings also suggest that T cells may respond to a broader range of TLR ligands than has
been thus far been considered, since functional outcomes may differ in responses to
specific TLR ligands.
CD4+CD25+ Regulatory T cells
The studies discussed thus far indicate that TLR ligands can promote more effective Tcell mediated immunity by acting directly on conventional CD4 and CD8 T cells to
enhance their respective effector functions. However, TLR ligands can also influence
CD4+CD25+ regulatory T cells (Treg). Treg are known to inhibit T cell effector responses
in vitro, and are critical in maintaining immune tolerance and preventing the development
of autoimmunity in vivo(Piccirillo & Shevach 2004). As in the case of effector T cells, TLR
ligands indirectly modulate regulatory T cell responses by promoting inflammatory
cytokine production in APCs, which can inhibit the suppressive capacity of Treg(Pasare &
Ruslan Medzhitov 2003). However, it is now clear that TLR ligands can also act directly on

Treg, though there are differences in the reported outcomes of these actions.
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The TLR2 ligand, Pam3CysSK4, can act directly on mouse Treg through TLR2 to
promote their expansion both in vitro and in vivo, which may relate to the reduced
numbers of Treg found in Myd88-/- and Tlr2-/- mice(Sutmuller et al. 2006). Yet while
promoting increased proliferation of Treg, Pam3CysSK4 also abrogates their suppressive
activity, which correlates with a transient suppression of Foxp3 expression(Liu et al. 2006).
It has also been found that direct TLR8 triggering of human Treg similarly prevents their
suppressive activity(Peng et al. 2005). It should be noted though that, in contrast to these
studies, others have found that signals through TLR2 and TLR5 can enhance the
suppressive function of Treg as well as Foxp3 expression(Crellin et al. 2005)(Zanin-Zhorov et
al. 2006).

While TLR ligands may influence suppression in co-culture experiments, this
potentially reflects the combined result of distinct effects on both conventional T cells
and regulatory T cells. Indeed, co-culture suppression assays in which MyD88-deficiency
was restricted to either the responder or Treg population showed that CpG DNA can act
directly on Treg to block their suppressive activity, but also acts on effector T cells to
render then resistant to suppression(LaRosa et al. 2007). Interestingly, once TLR ligands
are removed, Treg fully regain their suppressive phenotypes(Liu et al. 2006)(Sutmuller et al.
2006).

Summary
Overall, these findings suggest a model whereby TLR ligands can act on both effector
and regulatory T cells to directly promote T-cell mediated immune responses by
enhancing T cell effector functions and clonal expansion through increased proliferation,
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survival and a transient loss of suppression. These TLR ligands also serve to concurrently
expand the Treg population, which regains its suppressive capacity following clearance of
the TLR ligands and can then act to regulate the expanded effector T cell population at
the end of the immune response.
It is important, however, to consider a number of caveats when interpreting the
results of these in vitro studies. In order to show that TLR ligands are able to act directly
on T cells, these studies depended on using highly purified T cells. The importance of
eliminating APCs in these experiments highlights a significant issue: while TLR ligands
can act directly on T cells, their indirect effects through APCs generally overshadow their
direct effects on T cell activation in in vitro cultures. In addition, these studies generally
employ high concentrations of TLR ligands that greatly exceed physiological levels.
Furthermore, given that TLR signals appear to stimulate different responses in different
cell subsets, the overall consequence of TLR ligands on T cells in a mixed culture of cells
is less clear. Overall, these in vitro studies importantly showed that TLR signals have the
ability to directly stimulate T cell responses. However, the relevance of these signals
during a physiological immune response in vivo remained unclear. In particular, it was
not known whether direct TLR signaling contributes to initial T cell activation, effector
cell differentiation, proliferation, survival or the differentiation and maintenance of
memory cells during an immune response. These unresolved questions formed the basis
of my dissertation work.

MyD88 regulates systemic immune responses against pathogens
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Studies in mice lacking TLRs, or adapter proteins, such as MyD88, have shown that these
receptors play an important role in regulating systemic immune responses. MyD88deficient mice have greatly increased susceptibility to a number of eukaryotic,
prokaryotic and viral pathogens. These include Toxoplasma gondii(Scanga et al. 2002),
Mycobacterium tuberculosis,(Scanga et al. 2004) herpes simplex virus(Tengvall & Harandi
2008), murine cytomegalovirus(Delale et al. 2005), vesicular stomatitis virus (VSV)(Lang et
al. 2007), vaccinia virus(Zhu et al. 2007) and lymphocytic choriomeningitis virus

(LCMV)(Zhou et al. 2005).
In these infection models, the immune impairments associated with MyD88deficiency have generally been attributed to the importance of MyD88 in regulating
innate immune responses. However, in light of the recent studies demonstrating that
TLRs can directly modulate T cell responses, we thought it important to consider whether
defective adaptive immune responses in MyD88-deficient mice also reflects a T-cell
intrinsic role for MyD88. In this work, we use lymphocytic choriomeningitis virus
(LCMV) as a model infection in which to examine the relative contribution of MyD88 in
T cells to the overall antiviral T cell response. Using a series of adoptive transfer
experiments, we show that while MyD88 plays a significant T cell extrinsic role in
promoting T cell responses, it also play an important T cell intrinsic role in regulating T
cell expansion during the primary response to acute LCMV infection (Chapter 1). We
also use an inducible flox-cre system to inducibly delete MyD88 expression after the
initial phase of T cell expansion to show that MyD88 is not required for the
differentiation, maintenance and reactivation of memory T cells (Chapter 2).
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Table 1. TLRs, their ligands and localization

TLR

Classical ligands

Distribution and cellular localization

TLR1

Mycobacteria: tri-acyl peptides

Ubiquitous surface expression in both humans and
mice. Heterodimerizes with TLR2

TLR2

Gram positive bacteria: peptidoglycan,
lipoproteins

Broad surface expression in both humans and
mice. Also found in phagolysosomes.
Heterodimerizes with TLR1 and TLR6

TLR3

Viruses: double-stranded RNA
Synthetic: polyinosic polycytidylic acid
[Poly(I:C)]

Intracellular expression primarily on mDCs in
humans and monocytes and mesangial cells in
mice

TLR4

Gram negative bacteria: LPS
(involves coreceptors CD14, LBP and
MD-2)

Broad surface expression in both humans and
mice. Intracellular expression in gut epithelium.

TLR5

Bacteria: flagellin

Broad surface expression in both humans and mice
including gut epithelium.

TLR6

Mycoplasma: Diacyl lipoproteins

Primarily expressed on the surface of mDCs, mast
cells and B cells. Found in both mice and humans.
Heterodimerizes with TLR2

TLR7

Viruses: single-stranded RNA
Synthetic ligand: imidazoquinolines

Endosomal expression primarily by pDCs and B
cells in humans. Also expressed by mDCs in mice

TLR8

Viruses: single-stranded RNA
Synthetic ligand: imidazoquinolines

Endosomal expression by human myeloid cells, NK
cells and T cells. Not reported functional in mice

TLR9

Viruses and bacteria: double-stranded DNA
Synthetic: CpG olidodeoxynucleotides

Endosomal expression primarily on pDCs, B cells
and NK cells in humans. Broader tissue expression
in mice

TLR10

Unknown

Expressed primarily on the surface of pDCs and B
cells in humans. Not found in mice

TLR11

Toxoplasma gondii: profilin
Uropathogenic bacteria

Expressed on the surface of murine uroepithelium.
Not described in humans

References: (Hornung et al. 2002)(Ozinsky et al. 2000)(Takeda et al. 2003)(Iwaki et al. 2002)(Aliprantis et al. 1999)
(Patole et al. 2005)(Alexopoulou et al. 2001)(Muzio et al. 2000) (Jiang et al. 2000)(Akashi et al. 2000) (Hayashi et al.
2001)(Gewirtz et al. 2001) (Heil et al. 2004)(Jurk et al. 2002) (Hemmi et al. 2000) (Latz et al. 2004) (Yarovinsky et al.
2005)(Zhang et al. 2004)
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CHAPTER 2: Materials and Methods

Mice
C57BL/6 (B6), B6.PL-Thy1a/CyJ (B6 Thy1.1), B6.SJL-Ptprca Pepcb/BoyJ (B6 CD45.1),
B6.129-Tr2tm1Kir/J, ( Tlr2-/-), B6.B10ScN-Tlr4lps-del/JthJ, (Tlr4-/-), B6.129S7-Il1r1tm1Imx/J,
(IL1r-/-) and B6.129P2-Il18r1tm1Aki/J, (IL18r-/-) were purchased from The Jackson
Laboratory. Tlr9-/- mice were provided by Robert Eisenberg (University of
Pennsylvania)(Hemmi et al. 2000). Myd88-/- mice were provided by Shizuo Akira (Osaka
University)(Adachi et al. 1998). Myd88-/- were maintained as a breeding colony in our
facility and were crossed with B6 Thy1.1 and B6 CD45.1 to generate Thy1.1 and CD45.1
congenic Myd88-/- mice. P14 TCR transgenic mice, which possess CD8 T cells that
recognize the gp33 epitope of LCMV(Pircher et al. 1989), were provided by Hao Shen
(University of Pennsylvania) and were crossed to generate Thy1.1 congenic Myd88-/P14 mice.
Myd88flox/flox mice have been previously described and were provided by Dr.
Anthony DeFranco (UCSF) and backcrossed at least 7 generations onto the C57BL/6
background(Hou et al. 2008). R26RYFP reporter mice on a C57BL/6 background were
provided by Jonathan Maltzman (University of Pennsylvania). R26RYFP mice contain an
enhanced yellow fluorescent protein (YFP) gene inserted into the Gt(ROSA)26Sor
locus(Jeong et al. 2004). Expression of YFP is blocked by a loxP-flanked STOP fragment
placed between the Gt(ROSA)26Sor promoter and the Smo/EYFP sequence(Jeong et al.
2004). These strains were intercrossed to generate Myd88flox/flox R26RYFP mice, in which
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expression of Cre-recombinase allows deletion of MyD88 detectable by the YFP reporter.
CreT2 mice on a C57BL/6 background were provided by Jonathan Maltzman (University
of Pennsylvania). These mice express a fusion protein of Cre-recombinase fused to a
mutant estrogen receptor under transcriptional control of the ubiquitin promoter that is
expressed in all reported tissues(Ruzankina et al. 2007). This CreT2 fusion protein is
ordinarily restricted to the cytoplasm but can gain access to the nucleus following
exposure to 4-hydroxytamoxifen. CreT2 mice were crossed with Myd88-/- mice to
generate Myd88+/- CreT2 mice. These mice were then crossed with Myd88flox/flox R26RYFP
mice to generate Myd88flox/- R26RYFP CreT2 mice and Myd88flox/+ R26RYFP CreT2
controls. These mice allow tamoxifen-inducible deletion of MyD88, identified by YFP
expression. Since male CreT2 mice may occasionally express low levels of Cre
recombinase in germ cells in the absence of tamoxifen treatment (Jonathan Maltzman,
unpublished observations) we avoided using breeder mice that expressed both the CreT2
transgene and floxed Myd88 alleles. Thus, our breeding strategy was specifically
designed so that the CreT2 transgene was only expressed together with the floxed
MyD88 and R26RYFP reporter genes in experimental and but not in breeder mice.
Myd88flox/flox mice were also crossed with CD4 Cre mice that express Cre recombinase
under the control of the CD4 promoter(Lee et al. 2001) to generate mice with a T cellspecific deletion of MyD88. All colonies were maintained under specific pathogen free
conditions in accordance with the protocols of the Institutional Animal Care and Use
Committee of the University of Pennsylvania.
Mice were genotyped using DNA isolated from tail clippings or ear clippings.
Tissues were digested and DNA was purified using either a DNeasy Blood and Tissue Kit
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(Qiagen) or a REDExtract-N-Amp Tissue PCR Kit (Sigma) according to the
manufacturers’ instructions. PCR was performed using either PureTaq Ready-to-go PCR
beads (GE Healthcare) or the REDExtract-N-Amp Tissue PCR Kit (Sigma) according to
the manufacturers’ instructions. The following PCR primers were used to genotype
Myd88-/- mice: Myd88 forward 5’ GGT GGT GGT TGT TTC TGA CG 3’, MyD88
reverse 5’ AAG GCG GGT CCA GAA CCA GG 3’, Neo forward 5’ CGG GAG CGG
CGA TAC CGT AAA GC 3’, Neo reverse 5’ GCT TGG GTG GAG AGG CTA TTC GG
3’. The following PCR primers were used to genotype MyD88flox mice: forward: 5’ GTT
GTG TGT GTC CGA CCG T 3’, reverse: 5’ GTC AGA AAC AAC CAC CAC CAT GC
3’. The following PCR primers were used to genotype R26RYFP mice: ROSA1: 5’ AAA
GTC GCT CTG AGT TGT TAT 3’, ROSA2: 5’ GCG AAG AGT TTG TCC TCA ACC
3’, ROSA3: 5’ GGA GCG GGA GAA ATG GAT ATG 3’. The following PCR primers
were used to genotype CreT2 mice: hCre forward: 5’ TGG GCG GCA TGG TGC AAG
TT 3’, hCre reverse: 5’ CGG TGC TAA CCA GCG TTT TC 3’. Expression of the P14
TCR transgene and CD45 and Thy1 congenic markers was determined by bleeding mice
and using antibodies against V2 TCR, V8 TCR and the relevant congenic markers to
phenotype PBMCs by flow cytometry, as described below.

LCMV infection
Acute LCMV infection was induced by the Armstrong strain of LCMV (LCMV-Arm).
LCMV was grown, titered and provided by the labs of Hao Shen (University of
Pennsylvania) and E. John Wherry (The Wistar Institute, PA). Virus stocks were diluted
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to 4 X 105 P.F.U. in sterile PBS and 2 X 105 PFU were injected per mouse via
intraperitoneal injection. Secondary re-infection was induced by injecting 2 X 106 PFU of
LCMV Clone 13 (LCMV-CL13) intravenously into mice that had been infected with
LCMV-Arm 50-60 days earlier.

In vivo tamoxifen treatment
Tamoxifen (Sigma) was prepared by mixing in 1g/mL of ethanol. This mixture was then
diluted to 20mg/mL with corn oil and dissolved by incubating at 37oC for several hours
with constant mixing. To induce deletion, Myd88flox/- and Myd88flox/+ mice were treated
with 200g tamoxifen/g bodyweight for 5 consecutive days by oral gavage(Park et al.
2008). Mice were bled 5 days following the last day of treatment and successful treatment

was confirmed by the presence of YFP+ cells.

Western blotting to verify MyD88 deletion
MyD88flox/- and MyD88flox/+ mice were treated with tamoxifen as indicated above. 5 days
after the last day of treatment, spleens and lymph nodes were isolated from treated mice
and untreated controls and stained for flow cytometry as described below. The YFP+ and
YFP- populations were sorted from total splenocytes, CD4 T cells and CD8 T cells.
Sorted cells were first lysed at 4°C in lysis buffer composed of 50 mM Tris-HCL (pH
6.8), 0.2% 2-mercaptoethanol, 20% glycerol, 4% SDS, and 0.001% bromophenol blue
(Sigma-Aldrich). Cell lysates were clarified by centrifugation at 11,000 g for 10 minutes.
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Supernatants were boiled for 5 minutes, separated on a 10% SDS-PAGE at 1x106 cell
equivalents/well and blotted onto Hybond ECL nitrocellulose membranes (Amersham
Biosciences). Membranes were blocked for 30 minutes in 5% milk in TBST at room
temperature and then probed with anti-MyD88 antibody (2127, ProSci Inc.) at a 1:500
dilution in 3% milk in TBST overnight at 4°C. Membranes were washed and probed with
a horseradish peroxidase–conjugated anti-rabbit secondary antibody at 1:1,000 for 60
minutes at room temperature. Blots were visualized by enhanced chemiluminescence
(Roche Diagnostics) according to the manufacturer’s protocol. Antibodies were
subsequently stripped from membranes using Restore Western Blot Stripping Buffer
(Pierce Biotechnology) and reprobed as above with an anti-actin antibody at a 1:5000
dilution.

In vivo 5-bromo-2-deoxyuridine (BrdU) administration
For short term BrdU pulse (24 hours and under) mice were given an intraperitoneal
injection of 1mg BrdU (BD Biosciences) every 12 hours. For longer pulses mice were
given an initial intraperitoneal injection of 1mg BrdU (BD Biosciences) and were then
given a solution of 1mg/mL BrdU (Sigma) and 1mg/mL dextrose (Sigma) in their
drinking water. Water bottles were protected from light and changed every 72hrs. To
detect BrdU incorporation, splenocytes were isolated from treated mice. Following
staining of surface antigens as described below, cells were fixed, permeabilized and
stained for BrdU expression using the FITC BrdU flow kit (BD Pharmingen) according
to the manufacturer’s instructions.
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Antibodies, flow cytometry and cell sorting
Single cell suspensions were washed in FACS buffer (PBS + 1% FBS) and stained in
polystyrene round bottom tubes or in 96-well round bottom plates for 30 minutes at 4oC.
When staining with tetramers, cells were stained for 20 minutes at room temperature. The
following antibodies were used: FITC anti-CD44 (IM7), FITC-anti CD69 (H1.2F3),
FITC anti-CD45R/B220 (RA3-6132), FITC anti-CD19 (1D3), FITC anti-CD4 (RM4-4),
FITC anti-CD4 (GK1.5), FITC anti-CD8 (53.67), FITC anti-CD3e (17A2), FITC antiCD11b (M1/70), FITC anti-CD11c (N418), FITC-anti Gr1/Ly6G (RB6-8C5), FITC antiNK1.1 (PK136), FITC anti-TCR (Gl-3), FITC anti- Ly67 (Ter119), FITC anti-CD107a
(1D4B), FITC anti-CD107b (ABL-93), FITC anti-CD122 (TM-1), FITC anti-KLRG1
(2F1), FITC anti-V2 TCR (B20-1), FITC anti-BrdU, FITC anti-Bcl-xL (7B2.5), PE
anti-Annexin V, PE anti 41BB/CD137 (1AH2), PE anti-OX40/CD134 (OX86), PE antiICOS (7E.17G9), PE anti-CD40L/CD154 (MR-1), PE anti-PD1 (J43), PE anti-Fas/CD95
(MFL3), PE anti-CTLA4/CD152 (UC10-4F10-11), PE anti-CD25 (PC61) PE anti-CD127
(A7R34), PE anti-V8.1/V8.2 TCR (MR5-2), PE anti-Sca1/Ly-6A/E (E13-161.7), PE
anti IL-2 (JES6-5H4), PE anti-granzyme B (GB11), PE anti Bcl-2 (3F11), PerCP antiCD90.1 (OX7), PerCP-Cy5.5 anti-CD45.1 (A20), PerCP-Cy5.5 anti CD45.2 (104)
PerCP-Cy5.5 anti-CD127 (A7R34), PerCP anti-CD25 (PC61), APC anti-CD62L (MEL14), APC anti-cKit/CD117 (2B8), APC anti-IFN (XMG1.2), APC anti-TNF (MP6XT22), PE-Cy7 anti-CD62L (MEL-14), PE-Cy7 anti-CD90.2 (53-2.1), PE-Cy7 anti
CD45.1 (A20), PE-Cy7 anti IFN (XMG1.2), PE-Cy7 anti PD-1 (RMP1-30), Alexa
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Fluor® 700 anti-CD4 (L3T4), APC-Alexa Fluor® 750 anti-CD8 (53-6.7), APC-Alexa
Fluor® 750 anti-CD45.2 (104), APC-Alexa Fluor® 750 anti CD25 (PC61), Pacific
Blue® anti-CD44 (IM7), Pacific Blue® anti-CD8 (53-6.7) and Pacific Blue® anti IFN
(XMG1.2).
All antibodies were purchased from BD Biosciences, eBioscience or Biolegend except
for KLRG-1 (Beckman Coulter), anti-human Granzyme B (Caltag Laboratories), antiBcl-xL (Southern Biotech). APC conjugated H2-Db gp33, H2-Db np396 and H2-Db
gp276 tetramers were provided by Hao Shen and E. John Wherry.
Flow cytometric analysis was primarily performed on a modified FACS Canto
cytometer with an additional Violet laser (Beckton Dickinson). Some analysis was also
performed on FACS Calibur and LSR II cytometers (Beckton Dickinson). High speed
cell sorting was performed on a FACS Aria (Beckton Dickinson). Flow cytometric data
was analyzed using FlowJo software (Treestar Inc.).

Cell isolations for adoptive transfers and analysis
Spleens and lymph nodes were pooled from indicated donor mice and single cell
suspensions were prepared by crushing and filtering through 70M mesh. Red blood cells
were lysed using ACK lysing buffer (Lonza) and T cells were isolated using negative
selection MACS T cell isolation kits (Miltenyi Biosciences). Enriched T cells were
resuspended in HBSS and transferred into recipients via retro-orbital injection. For
polyclonal T cell transfer experiments 1 X 107 WT or Myd88-/- cells were transferred
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into B6 Thy1.1 recipients. For P14 cotransfer experiments purified Thy1 congenic WT
and Myd88-/- T cells were counted and combined at an equal ratio and transferred into
B6 CD45.1 congenic recipients. To examine T cell responses at the peak of expansion,
day 7 post infection, 2.5 X 104 combined P14 cells were transferred. To examine early T
cell proliferation, 1 X 106 combined CFSE-labeled P14 cells were transferred.
For progressive analysis of T cell differentiation, 5-6 drops of blood were serially
collected from infected mice via retro-orbital or sub-mandibular bleeds. Lymphocytes
were isolated using Histopaque 1083 (Sigma), resuspended in FACS buffer and stained
with antibodies for flow cytometry as indicated above. For terminal analysis mice were
sacrificed and spleens and lymph nodes were dissected. In some experiments liver, lung
and bone marrow were also collected and a peritoneal lavage was performed. Single cell
suspensions were prepared by crushing tissues and filtering through 70M mesh. Red
blood cells were lysed using ACK lysing buffer (Lonza) and in the case of cells from
liver, lung, bone marrow and peritoneal lavage, lymphocytes were enriched using
Histopaque 1083. Cells were then resuspended in FACS buffer and stained with
antibodies for flow cytometry as indicated above.

Generation of mixed bone marrow chimeras
Bone marrow was flushed from femurs and tibias of WT CD45.2 and Myd88-/- CD45.1
donor mice using a 20 gauge needle. Red blood cells were lysed using ACK lysing buffer
(Lonza) and T cells were depleted using MACS T cell isolation kits (Miltenyi
Biosciences). WT and Myd88-/- T cell depleted bone marrow was counted and combined
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at equal ratio. 1-2 X 106 cells were transferred into lethally irradiated (1000 rads) B6
CD45.2, Thy1.1 recipients. In some experiments, ACK lysed bone marrow was stained
with PE Sca1, APC cKit and a FITC lineage cocktail (CD4, CD8, CD3, TCR, CD19,
B220, NK1.1, CD11b, CD11c, Gr-1, Ter119) and the hematopoietic stem cell-containing
lineage-, Sca1+, cKit+ (LSK) population was sorted. Equal numbers of WT and Myd88-/LSKs were sorted and 2X104 combined LSKs were transferred into lethally irradiated
(1000 rads) B6 CD45.1 recipients. 12-16 weeks were allowed for immune reconstitution
before mice were used for experiments,

Ex vivo restimulation and assessment of T cell effector functions
Spleens were isolated from mice at the indicated time points following infection and
single cell suspensions were made as indicated above. LCMV derived peptides were
provided by Hao Shen and E. John Wherry and included GP33-41, GP61-80, NP396-404 and a
pooled peptide mixture comprising NP396-404, NP205-212, NP166-175, NP235-243, GP33-41,
GP276-286, GP118-125, GP92-101, and GP70-77 that accounts for almost all known LCMV
epitopes(Masopust et al. 2007). 3 X 106 splenocytes were cultured in round bottom plates
with 0.1g of the indicated LCMV derived peptides in the presence of 0.67L/mL of
Golgistop (containing monensin, BD Biosciences). In experiments to assess
degranulation, FITC anti-CD107a and anti-CD107b were also added at the start of
culture. Cells were harvested after 5-6 hours and surface stained. Cells were then fixed
and permeabilized using the BD Cytofix/Cytoperm kit according to the manufacturer’s
instructions. Cells were then stained with PE anti-IL2, APC anti-TNF and PE-Cy7 anti26

IFN. For granzyme B analysis cells were stained directly ex vivo without any
restimulation.

Assessing ex vivo T cell survival
Spleens were isolated from mice at the indicated time points following infection and
single cell suspensions were made as indicated above. Splenocytes were either examined
immediately ex vivo or were cultured overnight in RPMI 1640 with or without 10% FBS.
In experiments to examine whether cytokines could rescue cells from apoptosis, media
was supplemented with either 100U/mL recombinant mouse IL-2 (R&D Systems) or
1000U/mL Universal Type-I IFN (PBL Biomedical Laboratories) as indicated. ApoStat
(FITC-VD-FMK, R&D Systems) was added to cultures for the last 30 minutes of culture
as per the manufacturer’s instructions to detect total active caspases. After staining of
surface marker, cells were resuspended in 200L of annxein binding buffer with 4L of
annexin V PE (BD Pharmingen) and 7mL of the vital dye 7-AAD to assess apoptosis.

In vitro activation-induced cell death (AICD) assay
Total T cells were MACS purified from spleens and lymph nodes of naïve Myd88-/CD45.2 and congenic WT B6.CD45.1 mice as indicated above. Purified T cells were
combined at a 1:1 ratio and cultured with 1g/mL plate-bound CD3 and 1g/mL
soluble CD28 at a density of 3 X 106cells/mL/well in a 24-well plate. 100U/mL of IL-2
was added to the cells after 24 hours. Following another 24 hours, cells were harvested
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and live cells were isolated using Histopaque 1083 (Sigma). Live cells were re-plated at a
density of 1 X 106 per well in a 96 well round bottom plate. Cells were either allowed to
rest, or were restimulated with either 10g/mL plate-bound CD3, 1g/mL of soluble
Fas antibody (BD Biosciences), or 50ng/mL recombinant TNF (R&D Systems). Cells
were harvested at 18, 24 and 48hrs following restimulation. ApoStat (FITC-VD-FMK,
R&D Systems) was added to cultures for the last 30 minutes of culture as per the
manufacturer’s instructions to detect total active caspases. After staining of surface
marker, cells were resuspended in 200L of annxein binding buffer with 4L of annexin
V PE (BD Pharmingen) and 7mL of the vital dye 7-AAD to assess apoptosis. CD4 and
CD8 T cells were examined separately during analysis and WT and Myd88-/- cells were
distinguished on the basis of CD45.1 expression

Assessing the effects of in vitro stimulation of T cells with TLRs
Naïve (CD44low,CD62Lhigh,CD25low) CD4 or CD8 T cells were FACS purified from
pooled spleens and lymph nodes of WT or Myd88-/- mice. Sorted T cells were cultured
with 1g/mL plate-bound CD3 in the presence or absence of 1M CpG-ODN
(TCCATGACGTTCCTGACGTT) and 1000U/mL murine IFN-1 (PBL Biomedical
Laboratories) as indicated. After 48 hours, culture supernatants were collected to examine
levels of secreted IL-2 and IFN by ELISA and cells were washed from plates and lysed
using lysis buffer composed of 50 mM Tris-HCL (pH 6.8), 0.2% 2-mercaptoethanol, 20%
glycerol, 4% SDS, and 0.001% bromophenol blue (Sigma-Aldrich). Cell lysates were
separated on a 10% SDS-PAGE at 1x106 cell equivalents/well and blotted onto Hybond
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ECL nitrocellulose membranes (Amersham Biosciences) as indicated above. Blots were
probed with a rabbit anti-Bcl-xL antibody (Cell Signaling) followed by a horseradish
peroxidase–conjugated anti-rabbit secondary. Following visualization, antibodies were
stripped and blots were reprobed as above with an anti-actin antibody.

Examining naïve T cell responses to Type I IFNs
CD8 T cells were MACs purified from WT or Myd88-/- mice as indicated above. To
examine proximal signaling in response to stimulation with Type I IFNs, purified T cells
were either rested or stimulated with 1g/mL plate-bound CD3 for 24hrs. Cells were
then culture for 30 minutes in the presence or absence of 10000U/mL of murine IFN1
or 1000U/mL Universal Type-I IFN (PBL Biomedical Laboratories) as indicated in
figures. Cells were then lysed and lysates were separated on a 10% SDS-PAGE at 1x106
cell equivalents/well and blotted onto Hybond ECL nitrocellulose membranes as
indicated above. Blots were probed using a rabbit anti-phosphpo-STAT 3 antibody (Cell
Signaling) followed by a horseradish peroxidase–conjugated anti-rabbit secondary. After
visualization, antibodies were stripped and blots were reprobed as above using a rabbit
anti-phospho-STAT 1 antibody (Cell Signaling). Antibodies were once again stripped
and blots were reprobed using an anti-actin antibody.
To examine longer-term effects of Type-I IFNs, MACs purified WT or Myd88-/- CD8 T
cells were cultured for 72hrs with 0.3g/mL or plate-bound CD3 and 2.5g/mL platebound CD28 in the presence or absence of 10-1000U/mL Universal Type-I IFN (PBL
Biomedical Laboratories) or 5ng/mL IL-12 (R&D Systems). Following 72hrs of culture,
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cells were either stained with Annexin-V and 7AAD to assess viability, or were fixed and
permeabilized to examine levels of granzyme B and IFN by intracellular staining.

Quantitative PCR for apoptotic markers
Adoptively transferred WT and Myd88-/- P14 cells were sorted from recipients 4 days
after LCMV infection by FACS on the basis of congenic markers. RNA was purified
from the sorted cells using the RNeasy Mini Kit (Qiagen) according to the
manufacturer’s instructions. RNA was subsequently repurified and concentrated using the
RNeasy MinElute Cleanup Kit (Qiagen). RNA concentration and purity was measured on
the basis of absorption at 260nm and 280nm using a spectrophotometer. Equal amounts
of RNA were converted to cDNA using a RT2 First Strand Kit (SA Biosciences) and then
used in a Mouse Apoptosis PCR Array (stock # PAMM-012, SA Biosciences) according
to the manufacturer’s instructions. Amplification was performed using an ABI Prism
7000 thermocycler (Applied Biosystems) and analyzed using ABI Prism 7000 SDS
software (Applied Biosystems). Ct was calculated and normalized to the average Ct of
the housekeeping genes, actin, Gapdh and Hprt1. Normalized Ct of Myd88-/- and WT
test samples were then compared and expressed as a relative fold difference of Myd88-/P14/ WT P14.

Full genome microarray
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Adoptively transferred WT and Myd88-/- P14 cells were sorted and pooled from 20
recipients 5 days after LCMV infection by FACS on the basis of congenic markers. RNA
was purified from the sorted cells using the RNeasy Mini Kit (Qiagen) and subsequently
repurified and concentrated using the RNeasy MinElute Cleanup Kit (Qiagen) according
to the manufacturer’s instructions. RNA samples were given to the Functional Genomics
Core of the Diabetes and Endocrinology Research Center (University of Pennsylvania)
for subsequent processing. Functional Genomics Core staff verified RNA integrity using
an Agilent Bioanalyzer and performed a two-color Agilent microarray. WT and Myd88-/RNA samples were divided to perform mircoarrays in technical triplicates. Data were
filtered and normalized prior to calculation of fold-changes. The significance of foldchanges was assessed by comparing them to the variation in each gene across triplicates
using permutation tests. A fold-change of 1.5 or greater was used as a cutoff to generate a
list of differentially expressed genes. The gene lists that were over-expressed and underexpressed in Myd88-/- relative to WT P14 cells were then processed separately using the
Database for Annotation, Visualization, and Integrated Discovery (DAVID, NIH) to
generate functional annotation clusters(Dennis et al. 2003). Significance of associations
was determined based on the EASE score, a modified Fisher Exact P-value for gene
enrichment analysis.

Statistical analysis
A Student’s t-test was used to determine the statistical significance of differences
between data sets where indicated. A p value of less than 0.05 was considered significant.
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CHAPTER 3: MyD88 plays a T cell intrinsic role in controlling
primary CD8 T cell expansion during acute LCMV infection

Introduction
Lymphocytic choriomeningitis virus (LCMV) is the prototypic murine arenavirus
and is a natural mouse pathogen that has been extensively characterized as a viral
infection model. LCMV infection of adult mice can result in different outcomes
depending on the strain of the virus, the dose and route of infection and the background
strain of the host. The Armstrong strain of LCMV induces an acute infection in B6 mice
that elicits a dramatic expansion of CD8 T cells that play an important role in viral
clearance. A recent study has found that LCMV-specific effector cells divide at least 15
times and comprise over 80% of CD8 T cell pool at the peak of the response, 8 days after
infection(Masopust et al. 2007).
LCMV infection has routinely been employed to study adaptive immune
responses to viral infection and numerous reagents have been developed that allow the
analysis of T cell responses at the single cell level. The LCMV genome encodes a total of
4 proteins and examination of the nucleoprotein and glycoprotein sequences revealed
several potential CD8 T cell epitopes in B6 mice. This has resulted in the generation of
arrays of LCMV-derived peptides which, when coupled with intracellular cytokine
staining, can be used to examine effector cytokine production in response to specific viral
epitopes. More recently, MHC class I tetramers have been developed that allow antigen
specific CD8 T cells to be enumerated in the absence of a functional readout.
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Furthermore, a TCR that recognizes the gp33 epitope of LCMV in the context of H2-Db
has been cloned and used to generate the P14 TCR transgenic mouse(Pircher et al. 1989).
Together, these tools make LCMV an ideal model for examining in vivo T cell responses
to a natural, viral pathogen.
Myd88-/- mice have been shown to develop a greatly reduced frequency of
antigen-specific effector CD8 T cells following LCMV infection. This results in reduced
cytokine production and cytolytic activity, which is associated with impaired viral
clearance of LCMV-WE and high dose LCMV-Armstrong(Zhou et al. 2005). Similarly, the
spleens of mice lacking IRAK-4, the signaling kinase downstream of MyD88, have also
been found to contain fewer CD8 T cells following LCMV infection resulting in reduced
cytolytic activity and impaired viral clearance(Lye et al. 2008). Together, these studies
indicate an important role for TLR signaling pathways in controlling T cell responses to
LCMV.
In response to LCMV infection, Myd88-/- mice produce significantly lower levels
of pro-inflammatory cytokines, consistent with the importance of MyD88 in the innate
immune response. In particular, plasmacytoid dendritic cells in Myd88-/- mice produce
lower levels of Type I IFNs which, in turn, have been shown to play an important role in
promoting T cell expansion. Antigen presentation of LCMV-derived peptides may also
be impaired. Together, these defects in the innate immune response may be expected to
contribute greatly to the impaired adaptive immune response to LCMV in Myd88-/- mice
described earlier. However, in light of the studies discussed in Chapter 1, which
demonstrated that MyD88-dependent pathways can regulate T cell responses in vitro, I
33

wanted to examine whether the impaired T cell response also reflects a direct role for
MyD88 in T cells during LCMV infection. In the following sections we directly examine
the importance of T-cell intrinsic MyD88 expression during naïve T cell differentiation,
proliferation and survival during the phase of clonal expansion following acute LCMV
infection.

3.1 Myd88-/- mice mount greatly reduced T cell responses to LCMV
Infection of C57BL/6 (WT) mice with LCMV-Armstrong induces a dramatic expansion
of CD8 T cells peaking 8 days post infection. Consistent with earlier reports we found
greatly reduced CD8 T cell numbers in the spleens of Myd88-/- mice following LCMV
infection (Fig. 3.1A). Notably, the difference in cell numbers was restricted to cells that
expressed high levels of CD44, characteristic of antigen experienced cells.
To further characterize these defects we next used available reagents to
specifically examine antigen-specific T cells. We found a greatly reduced frequency of
antigen-specific IFN-producing CD8 T cells in Myd88-/- splenocytes following an ex
vivo restimulation with H-2Db restricted LCMV-derived peptides (Fig 3.1B). Similarly,
we found a reduced frequency of IFN-producing CD4 T cells in response to stimulation
with the I-Ab-restricted gp61-80 peptide (Fig 3.1B). While these findings appeared to
indicate a reduced frequency of antigen-specific cells it could also potentially reflect a
failure of antigen specific cells in Myd88-/- mice to differentiate into cytokine-producing
effector cells. To distinguish between these possibilities we used MHC class I tetramers
to enumerate CD8 T cells specific for known immunodominant LCMV epitopes
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independent of their functional responses. We found a greatly reduced percentage (Fig
3.1C) and absolute number (Fig 3.1D) of antigen specific cells in Myd88-/- mice.
These findings suggest that the absence of IFN producing cells primarily reflects
a reduced frequency of LCMV-specific CD8 T cells at the peak of the response.
However, it should be noted that the relative difference in the frequency of tetramerspecific cells between WT and Myd88-/- mice (Fig 3.1C) appears to be somewhat less
than the difference in the frequency of IFN producing cells (Fig 3.1B), suggesting that
MyD88 may also contribute to the development of T cell effector functions. In addition
to their reduced number, we also observed differences in phenotypic receptor expression
on LCMV-specific CD8 T cells from Myd88-/- mice. In particular, we found significantly
elevated levels of the inhibitory receptor PD-1 on Myd88-/- CD8 T cells, most notably
within the np396-specific population (Fig 3.1E). This complements the results of a recent
study that found that concurrent TLR stimulation promoted lower levels of PD-1
expression on CD8 T cells following peptide vaccination(Wong et al. 2009). Notably, we
found that these elevated levels of PD-1 appeared to be correlated with a more dramatic
reduction in the np396-specific population of T cells in Myd88-/- mice than the gp33 or
gp276-specific populations, suggesting that MyD88 expression regulates the pattern of
immunodominance in the T cell response. Overall, these findings suggest that MyD88
appears to control the frequency, function and phenotype of LCMV-specific T cells
following infection.
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3.2 The importance of MyD88 in LCMV cannot be attributed to individual TLR
pathways
Given that MyD88 is required for signaling through multiple TLR pathways we wished
to examine whether the phenotype of Myd88-/- mice following LCMV infection could be
recapitulated in mice lacking specific MyD88-dependent receptors. As discussed earlier,
B6 T cells have been shown to respond directly to ligands for TLR2 and TLR9 in vitro.
We therefore infected Tlr2-/- and Tlr9-/- mice to determine whether T cell responses to
LCMV are impaired in the absence of these TLR pathways. In contrast to the severely
impaired T cell response in Myd88-/- mice, we found no significant reduction in the
frequency (Fig 3.2A) or total number (Fig 3.2B) of antigen specific CD8 T cells in the
spleens of Tlr2-/- or Tlr9-/- mice following LCMV infection. In fact, Tlr2-/- splenocytes
showed an increased frequency of CD8 T cells and an increased frequency of tetramerspecific cells within the CD8 T cell population resulting in a significantly greater overall
number of tetramer-specific cells than WT mice (p = 0.02) (Fig 3.2B). CD8 T cells from
Tlr2-/- and Tlr9-/- mice also produced IFN following ex vivo restimulation with LCMVderived peptides suggesting that the absence of these TLR pathways does not impair CD8
T cell expansion or effector differentiation (Fig 3.2C). These findings are supported by a
recent study that also found that the phenotype of Myd88-/- mice was not recapitulated in
mice lacking individual TLR pathways(Jung et al. 2008).
In addition to TLR signaling, MyD88 also plays a role in signaling downstream of
the IL-1R family. Cytokines in this family, including IL-1 and IL-18, have been shown to
play a role in controlling T cell survival and effector differentiation(Adachi et al. 1998)(Li et
36

al. 2007)(Denton et al. 2007). We therefore examined T cell responses following LCMV

infection in IL1r-/- and IL18r-/- mice to see whether these pathways, rather than TLRs
may account for the importance of MyD88. We found no reduction in the frequency (Fig.
3.2A) or number (Fig 3.2B) of antigen specific CD8 T cells in IL1r-/- mice, and while
there were significantly fewer tetramer-specific CD8 T cells in the spleens of IL18r-/mice (p = 0.03), the CD8 T cell response was far larger than observed in Myd88-/- mice.
Furthermore, CD8 T cells from IL1r-/- and IL18r-/- produced IFN upon ex vivo
restimulation (Fig 3.2C) suggesting that these pathways are also dispensable for effector
differentiation. Together, these results suggest that the impaired T cell response to LCMV
infection in Myd88-/- mice cannot be narrowed down to the role of specific MyD88dependent receptors. In light of this finding, we decided to continue to focus on Myd88-/cells for subsequent studies.

3.3 Adoptively transferred WT T cells expand better than endogenous T cells in
Myd88-/- hosts
We have showed that MyD88 plays an important role in controlling T cell responses
following LCMV infection, but it was unclear whether this reflected a direct or indirect
role in T cells. As discussed earlier, the reduced levels of type I IFNs and other proinflammatory cytokines in Myd88-/- mice during LCMV infection suggest that the
MyD88-deficient innate immune compartment may not effectively support T cell
expansion and effector differentiation(Jung et al. 2008). However, given that MyD88dependent pathways can also directly regulate T cell functions, the impaired T cell
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response in Myd88-/- mice could potentially reflect an intrinsic role for MyD88 in T cells
during LCMV infection.
To examine the relative contribution of MyD88 in the innate immune
compartment, we transferred naïve WT CD8 T cells were into congenic, Myd88-/recipients, which were then infected with LCMV (Fig 3.3A). We found that adoptively
transferred WT CD8 T cells mounted a reduced response to LCMV infection in Myd88-/hosts compared to their response in WT controls, resulting in 2-fold fewer transferred
cells 8 days after infection (Fig 3.3B). This corresponded to a significantly reduced
frequency (Fig 3.3C) and number (Fig 3.3D) of antigen-specific, IFN-producing cells.
Notably, there was a greater reduction in the np396-responsive population than in the
gp33-responsive population suggesting that MyD88 in the host environment contributes
to the pattern of immunodominance in the T cell response.
The reduced frequency of IFN producing cells correlated with a reduced
frequency of LCMV-specific cells as identified by tetramer staining (Fig 3.3E),
indicating reduced expansion rather than a failure to differentiate into IFN-producing
effectors. Further examination of the phenotype of these tetramer-specific cells revealed
that WT T cells expressed higher levels of PD-1 in Myd88-/- hosts than in WT controls
(Fig 3.3F). This suggests that the elevated levels of PD-1 observed in Myd88-/- mice (Fig
3.1F) are primarily associated with the MyD88-deficient environment rather than an
intrinsic characteristic of the T cells.
Importantly however, while the donor WT T cells did not expand as greatly in
Myd88-/- hosts as in WT hosts, they expanded far better than the endogenous Myd88-/38

CD8 T cells as indicated by a greater relative percentage of tetramer-specific cells than
the endogenous Myd88-/- cells (Fig 3.3F). Therefore, while these results support earlier
studies suggesting that MyD88 plays an important, T cell-extrinsic role in supporting T
cell responses during LCMV infection, the absence of MyD88 in the host environment
does not entirely account for the reduced CD8 T cell response in Myd88-/- mice. This
suggests that the importance of MyD88 during LCMV infection may be attributable to
both T cell-extrinsic and T cell-intrinsic components.

3.4 Myd88-/- T cells fail to expand effectively when transferred to WT hosts
To more directly examine the potential contribution of MyD88 in T cells during LCMV
infection, we performed the reciprocal adoptive transfer of purified CD8 T cells from
naïve Myd88-/- mice into congenic WT recipients (Fig 3.4A). Despite the provision of a
WT APC compartment and pro-inflammatory cytokine milieu, we found that Myd88-/donor CD8 T cells did not expand as effectively as WT CD8 T cells in response to
LCMV, resulting in approximately 10-fold fewer donor cells 8 days after infection (Fig
3.4B). While the Myd88-/- donor population generated antigen-specific IFN-producing
effector cells, their frequency (Fig 3.4C) and overall number (Fig 3.4D) were
dramatically reduced. This also corresponded to a greatly reduced frequency of antigen
specific cells as detected by tetramer staining (Fig 3.4E), suggesting that MyD88
intrinsically regulates LCMV-specific T cell expansion rather than the development of
effector functions.
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When comparing these findings to our results in Fig. 3.3 it is striking to note that
the reduced expansion of Myd88-/- CD8 T cells in WT hosts is far more dramatic than the
reduced expansion of WT CD8 T cells in Myd88-/- hosts following LCMV infection.
Together, these reciprocal transfer experiments suggest that the T cell-intrinsic
expression of MyD88 is critical in regulating T cell expansion and is an essential
consideration in accounting for the reduced T cell responses observed in Myd88-/- mice.

3.5 The impaired LCMV response of Myd88-/- T cells does not result from a
developmental defect in a Myd88-/- environment
These adoptive transfer experiments indicate a T cell-intrinsic role for MyD88 during
acute LCMV infection. However, it was possible that T cell development in a MyD88deficient environment could cause persistent functional impairments, resulting in
diminished expansion of Myd88-/- LCMV-specific CD8 T cells despite transfer into a
WT environment. To address this potential issue we sorted the hematopoietic stem cellcontaining LSK populations from the bone marrow of Myd88-/- and Myd88+/+
littermates, combined them with congenically disparate WT LSKs and transferred them
into lethally irradiated recipients to generate WT/KO and WT/WT chimeras (Fig 3.5A).
These mixed bone marrow chimeras allowed us to examine the responses of WT and
Myd88-/- T cells that developed together in the same mouse.
We found that WT and Myd88-/- hematopoietic stem cells had repopulated the
hematopoietic compartment comparably by 16 weeks post transplant. Thus, the CD8 T
cell compartment contained an equivalent proportion of CD45.1 and CD45.2 cells in both
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WT/KO and WT/WT uninfected chimeras (Fig 3.5B and C). We found a similar
proportion of CD45.1 and CD45.2 cells in the CD4 T cell compartment of uninfected
chimeras. Following LCMV infection, however, we found that the Myd88-/- fraction of
the CD8 T cell compartment did not expand as effectively as the WT compartment,
resulting in a significant decrease in the relative proportion of Myd88-/- CD8 T cells in
WT/KO chimeras (Fig 3.5 B and C). Notably, overall T cell expansion following
infection was comparable in WT/KO and WT/WT chimeras (Fig 3.5C), suggesting that
the absence of MyD88 in half of the innate immune compartment did not significantly
impair the ability of the innate immune system to support T cell responses to LCMV.
The reduced expansion of the Myd88-/- T cell compartment WT/KO chimeras
corresponded to a lower frequency of LCMV-specific CD8 T cells as identified by
tetramers (Fig 3.5D). However, despite their reduced frequency, LCMV-specific Myd88/- CD8 T cells expressed comparable levels of PD-1 as WT cells (Fig 3.5E) and also
produced IFN in response to restimulation with H2-Db restricted LCMV derived
peptides (Fig 3.5F). These findings indicate, consistent with our earlier results, that
MyD88 regulates CD8 T cell expansion but not differentiation into functional effectors.
Notably, restimulation with the I-Ab restricted gp61-80 peptide showed a reduced
frequency of LCMV-specific CD4 T cells in the Myd88-/- compartment of WT/KO
chimeras (Fig 3.5F), suggesting that MyD88 intrinsically regulates both CD8 and CD4 T
cell expansion following LCMV infection.

3.6 Myd88-/- P14 transgenic T cells do not expand as effectively as WT P14 cells
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The results thus far show that MyD88 plays a T cell-intrinsic role in regulating T cell
expansion in response to LCMV infection. Since these experiments examined naturally
occurring LCMV-specific T cell clones in a polyclonal response, it remained possible
that T cell population developed differences in its TCR repertoire in the absence of
MyD88, which subsequently influenced its response to infection. To circumvent potential
repertoire differences in the polyclonal Myd88-/- T cell population, we crossed Myd88-/mice with P14-TCR transgenic mice, whose T cells recognize the LCMV-derived gp3341 epitope. By further crossing these mice onto congenic backgrounds we were able to
isolate WT and Myd88-/- P14 cells that could be distinguished on the basis of
Thy1.1/Thy1/2 disparity. Combining these cells and co-transferring them into congenic
WT recipients allowed us to directly compare the responses of a monoclonal population
of WT and Myd88-/- cells within the same mouse (Fig 3.6A).
The adoptively transferred P14 population expanded dramatically in response to
LCMV infection, but there were 10-fold more WT than Myd88-/- P14 cells in the spleens
of mice at the peak of the response (Fig 3.6B), consistent with the reduced expansion in
the polyclonal Myd88-/- T cell repertoire. We wanted to confirm that the reduced number
of Myd88-/- P14 cells in the spleens of infected mice did not reflect their sequestration in
other tissues. Although we noted some differences in their relative tissue distributions,
the percentage of Myd88-/-, relative to WT, P14 cells was also reduced in the peripheral
lymph nodes, peritoneum and liver of infected mice, suggesting that their reduced
numbers truly reflected reduced expansion rather than differential trafficking.
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3.7 Myd88-/- P14 T cells develop effector phenotype and functions following LCMV
infection.
The ability to clearly distinguish the transferred P14 cells of congenic markers allowed us
to examine whether the reduced expansion of the Myd88-/- cells was associated with
differences in their effector phenotype or functions. We found no differences in the
expression of the T cell costimulatory receptors 41-BB, OX-40, ICOS, CD27 or CD40L
(Fig 3.7A). Similarly, we found no differences in the expression of inhibitory receptors
PD-1, Fas, or CTLA-4 (Fig 3.7B) or the cytokine receptors CD25, CD127 or CD122 (Fig
3.7C). These results suggest that the reduced expansion of Myd88-/- P14 cells is not a
secondary effect of reduced costimulation or cytokine signaling. We also found that
Myd88-/- P14 cells upregulated granzyme B expression and produced IFN and TNF
comparably to WT P14 cells (Fig 3.7D). Thus, consistent with our earlier results with
polyclonal T cell adoptive transfer and mixed bone marrow chimeras, MyD88 appears to
intrinsically regulate CD8 T cell expansion following LCMV infection but not
differentiation into functional effectors.

3.8 Myd88-/- T cells proliferate comparably to WT T cells in response to LCMV but
fail to accumulate.
Our results thus far show greatly reduced clonal expansion of Myd88-/- CD8 T cell in
response to LCMV. T cell numbers at peak expansion reflect the combined effects of
proliferation and cell survival, thus we sought to examine which of these processes
involved MyD88. At the peak of the response, the majority of the CD8 T cell population
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in WT mice is comprised of rapidly cycling effector cells, a large proportion of which
incorporate BrdU during a 24 hour labeling period. In contrast, only a small proportion of
the CD8 T cells in Myd88-/- mice incorporated BrdU, consistent with a reduced
frequency of rapidly expanding effector T cells (Fig. 3.8A). This was consistent with the
reduced proportion of LCMV-specific effectors in the CD8 T cell population of Myd88-/mice (Fig. 3.1). However, examination of the tetramer-specific cells revealed that the
small population of LCMV-specific Myd88-/- CD8 T cells incorporated BrdU
comparably to WT CD8 T cells (Fig. 3.8B). This suggested that LCMV-specific T cells
in Myd88-/- mice proliferated at a normal rate, implying that their dramatically lower
numbers reflect impaired survival.
To more comprehensively examine cell proliferation, we co-transferred CFSElabeled WT and Myd88-/- P14 cells into congenic hosts to examine early proliferation in
response to LCMV infection. No spontaneous proliferation was observed upon transfer,
since both WT and Myd88-/- P14 cells remained CFSEhigh in uninfected recipients (Fig.
3.8C). At 72hrs following LCMV infection, both WT and Myd88-/- P14 cells proliferated
rapidly and underwent multiple rounds of division, diluting CFSE beyond the level of
detection by 96hrs, suggesting that WT and Myd88-/- P14 cells proliferate comparably in
response to LCMV. While division profiles appeared similar, the relative proportion of
Myd88-/- to WT P14 cells decreased over time, corresponding to reduced accumulation
of Myd88-/- T cells (Fig 3.8C and 3.8D). The reduced numbers of Myd88-/- P14 cells
became most apparent by day 4 post infection, at which point proliferation could no
longer be resolved by CFSE dilution. As it was possible that Myd88-/- T cells proliferated
normally for the first 7-8 rounds of division but subsequently stopped proliferating earlier
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than WT T cells, we used BrdU to compare the proportion of transferred WT and Myd88/- P14 cells that were actively cycling at later time points. We found that a similar
percentage of the adoptively transferred WT and Myd88-/- P14 cells incorporated BrdU
during a 12hr labeling period on days 4, 5 and 6 following LCMV infection (Fig 3.8E).
Thus, the capacity for proliferation between the two populations appeared to be similar
throughout the period during which the number of WT P14 cells greatly exceeded the
number of Myd88-/- P14 cells.

3.9 Antigen specific Myd88-/- T cells from LCMV infected mice exhibit increased
spontaneous apoptosis.
Reduced accumulation of LCMV-specific Myd88-/- T cells despite comparable
proliferation indicated reduced survival. To directly examine the survival of transferred
Myd88-/- and WT P14 cells following LCMV infection, we compared their viability
using light scatter properties, annxein V staining and caspase activation. Surprisingly, we
observed no significant differences in the viability of WT and Myd88-/- P14 cells directly
ex vivo at any of the time points examined (Fig 3.9A, left panels and data not shown).
Since this could potentially reflect the rapid clearance of apoptotic cells in vivo, we
isolated splenocytes from infected recipients during the period of T cell expansion and
cultured them ex vivo. Following 20hrs of culture ex vivo we found significantly reduced
survival of the Myd88-/- P14 cell (Fig 3.9A right panels). This reduced survival resulted
in a decline in the relative ratio of live Myd88-/- to WT P14 cells during the culture
period, consistent with the reduced accumulation of Myd88-/- P14 cells seen in vivo.
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Together, these data indicate that the reduced number of Myd88-/- T cells following
LCMV infection primarily reflects impaired survival, rather than impaired proliferation.

3.10 Myd88-/- P14 cells do not exhibit differences in the survival molecules Bcl-xL,
Bcl-2 or Bim.
The in vitro studies described earlier showed that TLR ligands can act directly on T cells
to increase survival through upregulation of the anti-apoptotic protein, Bcl-xL(Gelman et
al. 2004)(Cottalorda et al. 2006). We therefore hypothesized that the reduced survival of

Myd88-/- CD8 T cells following LCMV infection may be associated with reduced levels
of Bcl-xL. However, we did not find significant differences in the expression of the BclxL between WT or Myd88-/- P14 cells by intracellular staining (fig. 3.10A). Recent
reports have also demonstrated that T cell survival and contraction following LCMV
infection are regulated by the anti-apoptotic molecule Bcl-2 and the pro-apoptotic BH3
only protein, Bim(Wojciechowski et al. 2006)(Wojciechowski et al. 2007). We therefore also
examined the levels of these molecules but did not find significant differences in their
expression between WT and Myd88-/- P14 cells (fig 3.10A).
Since the resolution offered by intracellular cytokine staining may not be
adequate to detect more subtle differences in the level of expression of these apoptotic
proteins we also decided to examine their RNA expression using real-time, quantitative
PCR. We sorted WT and Myd88-/- P14 cells from infected recipients 4 days after
infection and examined the expression of multiple apoptosis-related genes using an
apoptosis PCR array. Using this assay we found no notable differences between WT and
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Myd88-/- P14 cells in the expression of Bcl-2, Bcl-xL or in other pro and anti-apoptotic
Bcl-2 family members (Fig. 3.10B). It should be noted however, that the RNA yields
from the sorted cells were in the lower end of the range recommended to be used in these
PCR arrays, which potentially reduces the sensitivity of the assay.

3.11 WT and Myd88-/- T cells are comparably sensitive to Fas induced cell death.
We have already shown that the reduced expansion of Myd88-/- T cells following LCMV
infection is not observed in mice lacking individual MyD88-dependent TLR or cytokine
receptors (Section 3.2). While this could potentially reflect the redundancy of multiple
TLR or cytokine pathways during in vivo immune responses, we also considered that the
importance of MyD88 during LCMV infection might be related to a role in alternative
signaling pathways. As discussed earlier, MyD88 has been shown to participate in Fasinduced signaling pathways in macrophages and fibroblasts due to its ability to interact
with other death domain containing proteins. It has been shown that, as a result of these
homotypic death-domain interactions, the expression of FADD can inhibit signaling
through TLRs by sequestering MyD88 away from TLR signaling pathways(Zhande et al.
2007). We therefore hypothesized that the expression of MyD88 and its interaction with

FADD may reciprocally inhibit signaling through Fas, thereby potentially rendering
Myd88-/- T cell hyperesponsive to Fas induced apoptosis. Fas has recently been shown to
contribute to the contraction of the CD8 T cell response following LCMV infection,
suggesting that Fas-signaling is a potentially relevant pathway of apoptosis in LCMVspecific T cells(Zhou et al. 2002)(L. T. Nguyen et al. 2000)(Weant et al. 2008). TNF-induced
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signaling has been shown to play a role in down-regulating the CD8 T cell response
following LCMV infection(Nguyen et al. 2000)(Singh & Suresh 2007) and signals
downstream of the TNFRs also involve death domain-containing proteins(Hsu et al.
1995)(Micheau & Tschopp 2003), raising the potential for interactions with MyD88. While

we had already found that Fas expression was comparable between WT and Myd88-/P14 T cells following infection (fig. 3.7B), this did not address potential differences in
signaling downstream of the Fas receptors. We therefore hypothesized that enhanced
signaling through Fas or TNF pathways may account for the increased apoptosis of
Myd88-/- T cells following LCMV infection.
Naïve T cells upregulate Fas expression in response to TCR-induced activation in
the presence of IL-2(Refaeli et al. 1998). Following restimulation, these recently activated
T cell undergo Fas-mediated apoptosis in a process termed activation induced cell death
(AICD) (Van Parijs et al. 1996)(Refaeli et al. 1998). We therefore employed an in vitro AICD
assay to directly compare the susceptibility of WT and Myd88-/- T cells to Fas-induced
cell death. We used a coculture system of congenically marked cells so that WT and
Myd88-/- T cells would be exposed to identical stimuli throughout the experiment. Using
this assay, we found no differences in AICD of WT and Myd88-/- CD4 or CD8 T cells
following restimulation with high-doses of anti-CD3 antibody, as assessed by both
Annexin V staining and the detection of activate caspases (Fig 3.11A). To address the
potential caveat that TCR induced AICD was not occurring through Fas, we also
stimulated activated cells with anti-Fas antibody or recombinant TNF to directly induce
Fas or TNFR-induced cell death. Consistent with our results with TCR-induced AICD,
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we found no differences in apoptosis or caspase activation between WT and Myd88-/cells (Fig 3.11A). These results show that WT and Myd88-/- T cells are comparably
susceptible to Fas and TNF induced apoptosis, suggesting that enhanced signaling
through these pathways does not account for the increased apoptosis of Myd88-/- T cells
following LCMV infection.

3.12 WT and Myd88-/- T cells show comparable responses to Type I IFNs
Our results suggests that the importance of MyD88 in supporting T cell survival during
LCMV infection may not be related to its traditional role in TLR or IL1R family cytokine
signaling, or to a role in Fas or TNFR signaling. In considering other potential roles for
MyD88 in T cells, we noted that the phenotype of Myd88-/- CD8 T cells following
LCMV infection was strikingly similar to that of T cells lacking the type I IFN receptor.
Similarly to Myd88-/- P14 cells, in comparison to WT P14 cells, IFNR-/- P14 cells have
been found to undergo increased apoptosis during LCMV infection, which results in
greatly diminished expansion despite comparable proliferation(Kolumam et al.
2005)(Aichele et al. 2006). Given these similarities, we considered whether MyD88 may be

playing a role in IFN-induced signaling pathways in T cells.
As discussed earlier, MyD88-dependent signals have been shown to play an
important role in the induction of Type-I IFN production in APCs through the
recruitment of IRF1, 5 and 7(Takaoka et al. 2005)(Honda et al. 2004). However, a role of
MyD88 downstream of signaling through IFN-IR is less clear. A recent study found that
IFN treatment enhanced human B cell responses to TLR9 stimulation through
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upregulation of MyD88 expression(Giordani et al. 2009). We therefore considered whether
an element of the IFN-I induced survival program in LCMV-specific T cells occurred as
a result of increased signaling through a MyD88-dependent signaling pathway. To test
this possibility we examined whether IFN, in analogy to B cells, promotes enhanced
signaling through MyD88-dependent TLR pathways in T cells. As discussed earlier,
treatment of TCR-activated CD4 and CD8 T cells with ligands for TLR2 and TLR9
promotes enhanced survival associated with Bcl-xL upregulation(Gelman et al.
2004)(Cottalorda et al. 2006). Using Bcl-xL upregulation as a readout for T cell responses

to TLR stimulation, we found that IFN did not appreciably enhance MyD88-dependent
signaling in T cells (Fig 3.12A).
While it did not appear that IFN enhanced MyD88-dependent, TLR-induced
signaling in T cells, we considered the reciprocal possibility that MyD88 may play a role
in supporting IFNR-induced signals. TLR stimulation has been shown to induce STAT1
phosphorylation in macrophages through a MyD88-dependent mechanism(Toshchakov et
al. 2002)(Rhee et al. 2003). However, we found that Myd88-/- and WT T cells comparably

phosphorylated STAT1 in response to stimulation with IFN, suggesting that MyD88 is
not required for STAT1 phosphorylation in T cells (Fig 3.12B). Since the pro-survival
effects of IFN-induced signaling in T cells have been attributed to STAT3
signaling(Tanabe et al. 2005) we also examined this pathway and found that Myd88-/- T
cells similarly did not have a defect in STAT3 phosphorylation following IFN
stimulation (Fig 3.12B).
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These experiments suggested that Myd88-/- T cells did not have a defect in
inducing proximal signals in response to IFN, but did not rule out a potential role for
MyD88 in regulating IFN-induced signals further downstream. To address this issue, we
compared longer term responses of WT and Myd88-/- T cells to IFN-stimulation.
Consistent with earlier reports(Curtsinger et al. 2005), we found that IFN-I and IL-12
promoted increased survival and granzyme B upregulation during in vitro CD8 T cell
activation and we found no reduction in these responses in Myd88-/- T cells (Fig. 3.12C).
While these results suggested that MyD88 was not required for type I IFN signaling in T
cells, we also considered the possibility that MyD88 may play a role in IFN-signaling
specifically in LCMV-specific T cells. We therefore compared the effects of type I IFNs
on adoptively co-transferred WT and Myd88-/- P14 cells isolated from LCMV infected
recipients. Consistent with its role in promoting survival, we found that treatment with
type I IFNs was able to rescue Myd88-/- P14 T cells from the spontaneous cell death that
we had observed following ex vivo culture (Fig. 3.12D). Together, these results suggest
that MyD88 is not required for IFN-induced signals in T cells, indicating that reduced
responses to type I IFNs do not account for the reduced survival of Myd88-/- T cells
following LCMV infection.

3.13 Genome-wide microarray suggests differences in the expression of lipid
phosphates and calcium signaling molecules in Myd88-/- P14 cells following LCMV
infection
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Since our studies had failed to identify a specific mechanism accounting for the reduced
survival of Myd88-/- T cells, we decided to perform a full-genome microarray, theorizing
that differentially expressed genes in Myd88-/- cells may provide insight into the role of
MyD88 during LCMV infection. We therefore sorted adoptively cotransferred WT and
Myd88-/- P14 cells from LCMV infected recipients, isolated RNA and performed an
Agilent microarray to examine genome-wide differences in gene expression. We hoped to
examine cells early in the response, reasoning that differences in the expression of
relevant genes would precede differences in survival, however day 5 post infection was
the earliest time point at which adoptively transferred P14 cells had expanded enough to
allow us to sort sufficient cells for analysis.
Overall, we noted that gene expression between WT and Myd88-/- P14 cells was
fairly similar. We found a total of 116 genes that were overexpressed in Myd88-/- relative
to WT P14 cells and 118 genes that were underexpressed with a fold change of 1.5 or
greater. Functional annotation clustering analysis of these genes using the NIH DAVID
database (Huang et al. 2009)(Dennis et al. 2003) identified 11 functionally related groups
with an enrichment score of 1.0 or greater. Consistent with our earlier findings, we did
not observe significant differences in genes related to TLR expression, Bcl-2 family
members or type I IFN signaling. Amongst genes that were over-expressed in Myd88-/cells we observed an enrichment of lipid phosphatases involved in phosphotidylinositol
signaling (Fig 3.13A). Amongst genes that were underexpressed we observed enrichment
of genes involved in calcium signaling (Fig 3.13B) and in amino acid metabolism (Fig
3.13C). We also noted reduced expression of Myd88 and associated inflammatory genes
(Fig 3.13D).
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Overall, these microarray results support our earlier experiments, suggesting that
MyD88 may be acting outside of its traditional role in TLR signaling during LCMV
infection. Specifically, MyD88 may be contributing to calcium signaling pathways or
amino acid metabolism, raising the possibility that defects in these pathways may account
for the reduced survival of Myd88-/- T cells during LCMV infection. However, a number
of caveats must be considered when interpreting these data. Firstly, while microarrays
were performed in triplicate, they involved only a single sample of WT P14 RNA and
Myd88-/- P14 RNA from 20 pooled infected recipients, making statistical significance
difficult to assess. In addition, since cells were examined day 5 post infection, at which
point differences in apoptosis and accumulation had already manifested, it is possible that
these differences in gene expression represent consequences, rather than causes of the
reduced survival of Myd88-/- cells. Furthermore, since there is considerable cellular
heterogeneity in the LCMV response, it is possible that the Myd88-/- P14 cells that are
present at this point in the response have already been selected for survival, eliminating
the cells that are most susceptible to apoptosis from the analysis. Lastly, since this
comparison did not include naïve WT and Myd88-/- P14 cells from uninfected animals, it
is unclear which of these differentially expressed genes reflect basal differences in
Myd88-/- T cells versus those that develop during LCMV infection.

Summary
Acute LCMV infection ordinarily elicits a robust expansion of virus-specific CD8 T
cells, which play an important role in viral clearance. This expansion is critically
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dependent on the presence of MyD88. The results in this chapter support a T cellextrinsic role for MyD88 in regulating T cell responses, as evidenced by the reduced
expansion and a shift in the pattern of immunodominance during the response of WT
CD8 T cells to LCMV infection in a Myd88-/- host (Section 3.3). This likely reflects
reduced production of type I IFNs and other pro-inflammatory cytokines by Myd88-/APCs(Jung et al. 2008), which have been shown to be important in regulating T cell
expansion. Importantly, however, our results using polyclonal and TCR transgenic
adoptive transfers and mixed bone marrow chimeras show that MyD88 also plays a
critical, T cell-intrinsic role in supporting the accumulation of antigen specific CD8 T
cells during the response to acute LCMV infection.
Earlier studies have shown that MyD88-dependent signals delivered through TLR
stimulation can directly regulate CD4 and CD8 T cell responses in vitro. While our
results in this chapter extend these findings to show that MyD88-dependent signals in T
cells are important during a physiological immune response to an infection in vivo, there
are some notable differences between our findings and those suggested by earlier in vitro
studies. Costimulation of naïve mouse T cells through TLR2 and TLR9 was shown to
augment proliferation, survival and the production of effector cytokines and granzyme B.
In contrast to these studies, our results indicate that MyD88-dependent signals are not
required for proliferation or the acquisition of effector functions. Instead, the importance
of MyD88 appears to be limited to a critical role in controlling the survival of effector T
cells, thereby supporting their sustained expansion and accumulation.
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Another notable finding in this chapter is that the dramatically reduced
accumulation of Myd88-/- effector cells was not recapitulated by the absence of signals
through TLR2, TLR9 or IL-1R family members. Thus, the upstream mediators of
MyD88-dependent signals in T cells during LCMV infection may not be the TLR that
have been suggested by in vitro studies. Furthermore, while TLR-induced survival
pathways have been associated with the upregulated of Bcl-xL in vitro, we did not
observe notable differences in Bcl-xL expression between WT and Myd88-/- T cells
following LCMV infection. In addition, the increased apoptosis of Myd88-/- T cells
following LCMV infection was not associated with an increased sensitivity to Fas
mediated apoptosis or reduced responsiveness to type I IFNs. Differences in global gene
expression instead indicate increased lipid phosphotase activity and reduced calcium
signaling and amino acid metabolism in Myd88-/- T cells.
In conclusion, the findings in this chapter clearly demonstrate a previously
unappreciated, T cell intrinsic role for MyD88 in regulating T cell expansion during and
in vivo immune response to LCMV infection. While MyD88 expression in CD8 T cells
during LCMV infection appears to be dispensable for initial activation, proliferation, and
differentiation effector T cells, it is required for their survival and accumulation. The identity of
the upstream stimuli and downstream signals that link MyD88 to T cell survival remain unclear
and raise the possibility that MyD88 may function in an as yet undefined fashion outside of its
traditional role in TLR signaling during LCMV infection.
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Figure 3.1. Myd88-/- mice mount greatly reduced T cell responses to LCMV. WT and
Myd88-/- B6 mice were infected with LCMV-Arm and splenocytes were purified 8 days after
infection. (A) CD8 T cells were enumerated using antibodies against CD8a and CD44. Data
represent mean +/- S.D. for at least 10 mice. (B) Splenocytes were restimulated ex vivo with the
indicated LCMV-derived peptides and antigen-specific IFN production was assessed. (C-D)
Gated CD8 T cells were analyzed with the indicated tetramers to determine the frequency (C) and
number (D) of LCMV-specific CD8 T cells. Data represent mean +/- S.D of at least 10 mice. (E)
PD-1 expression on tetramer-specific cells in WT and Myd88-/- mice was compared.
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Figure 3.2. The phenotype of Myd88-/- mice following LCMV infection is not recapitulated
by Tlr2-/-, Tlr9-/-, IL-1r-/- or IL-18r-/- mice. The indicated mice were infected with LCMVArm and splenocytes were purified 8 days after infection. (A-B) Gated CD8 T cells were
analyzed with the indicated tetramers to determine the frequency (A) and number (B) of LCMVspecific CD8 T cells. Data represent mean +/- S.D of at least 5 mice. Splenocytes were
restimulated ex vivo with the indicated peptides and CD8 T cell IFN production was assessed.
57

Figure 3.3. WT CD8 T cells are able to expand and develop effector functions in response to
LCMV in Myd88-/- hosts. (A) Experimental design. Splenocytes were examined 8 days after
infection. (B) The number of donor cells per spleen was enumerated. Data represent mean +/- SD
of at least 5 mice. (C-D) Splenocytes were restimulated with the indicated LCMV-derived
peptides and the frequency (C) and number (D) of IFN-producing donor cells was determined. p
< 0.05 for all values relative to corresponding WT controls. (E) The frequency of tetramerspecific cells in the donor and host CD8 populations was compared. (F) PD-1 expression was
examined on donor and host tetramer+ CD8 T cells. Data are representative of at least 5 mice.
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Figure 3.4. Myd88-/- CD8 T cells do not effectively expand in response to LCMV infection in
WT hosts. (A) Experimental design. Splenocytes were examined 8 days after infection. (B) The
number of adoptively transferred cells per spleen was enumerated. Data represent mean +/- SD of
5 mice. (C and D) Splenocytes were restimulated with the indicated LCMV-derived peptides and
the frequency (C) and number (D) of IFN-producing donor cells was determined. p < 0.01 for all
values relative to corresponding WT controls. (E) The frequency of tetramer-specific cells in the
donor and host CD8 T cell populations was compared. Data are representative of 5 mice per
group.
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Figure 3.5. Myd88-/- T cell defects following LCMV infection do not arise from
development in a MyD88-deficient environment. (A) Experimental design. Splenocytes were
examined 8 days after infection. (B-C) The ratio (B) and number (C) of CD45.1+ and CD45.2+
CD8 T cells was compared in infected and uninfected chimeras. Data show mean +/- SD of 5
mice per group. (D) Tetramers were used to compare the frequency of LCMV-specific CD8 T
cells within the CD45.1+ and CD45.2+ populations in the same mouse.(E) PD-1 expression on
the tetramer+ CD8 T cells within the CD45.1+ and CD45.2+ in the same mouse was compared.
Data are representative of 5 mice and differences in MFI were not significant. (F) Splenocytes
were restimulated with the indicated peptides to examine LCMV-specific IFN production by
WT and Myd88-/- CD8 T cells in the same mouse. Data are representative of 5 mice and p < 0.01
for all stimulation conditions.
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Figure 3.6. Myd88-/- P14 TCR transgenic T cells do not expand effectively in response to
LCMV infection. (A) Experimental design. (B) The relative proportion of donor Myd88-/- P14 to
WT P14 cells was compared on the basis of congenic Thy1.1 expression before and after LCMV
infection. (C) The frequency of Myd88-/- P14 and WT P14 cells within the CD8 T cell population
isolated from the indicated tissue compartment was determined using CD45.2 and Thy1.1
congenic marker. Data show mean +/- SD of 5 recipient mice.
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Figure 3.7. Myd88-/- P14 TCR transgenic T cells develop a normal effector phenotype and
effector functions following LCMV infection. Naïve Myd88-/- P14 and WT P14 cells were cotransferred as in Fig. 3.6 and donor derived cells were examined in the spleens of recipients 7
days after LCMV infection. (A-C) The expression of the indicated phenotypic markers was. (D)
Granzyme B levels were compared on Myd88-/- P14 and WT P14 cells in the same mouse by
intracellular staining directly ex vivo. Splenocytes were restimulated with gp33-41 peptide and
IFN and TNF production by Myd88-/- P14 and WT P14 cells in the same mouse were
compared by intracellular staining. All data are representative of 5 mice. No statistically
significant differences in MFI were found.
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Figure 3.8. Myd88-/- and
WT CD8 T cells
proliferate comparably
following LCMV infection.
(A-B) WT and Myd88-/mice were infected with
LCMV and given a 24hr
BrdU-pulse prior to
sacrifice on day 8 post
infection. BrdU
incorporation by (A) overall
CD8 T cells and (B) gated
tetramer-specific cells was
compared. Data show mean
+/- SD of 4 mice. (C and D)
CFSE-labeled congenic WT
and Myd88-/- P14 cells
were co-transferred into WT
recipients which were infected with LCMV 18hrs later. The division profiles (C) and
numbers (D) of WT and Myd88-/- P14 cells were compared in the spleens at the indicated
time points. Data show mean +/- SD of 5 mice at each time point. (E) WT and Myd88-/- P14
cells were co-transferred as in (C). Following a 12hr BrdU pulse, recipients were sacrificed at
the indicated time points and BrdU incorporation by donor WT and Myd88-/- P14 cells was
compared. Data show mean +/- SD of 4 mice at each time point.
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Figure 3.9. Myd88-/- CD8 cells exhibit decreased viability following LCMV infection. Naïve
WT and congenic Myd88-/- P14 cells were co-transferred into WT recipients as in Figure 3.8C.
Splenocytes were isolated 4 days following infection and the viability of gated WT and Myd88-/P14 cells was assessed by scatter properties, annexin V staining and the detection of total active
caspases. Cells were examined either immediately ex vivo (left panels) or following a 20hr culture
in the absence of exogenous peptides or cytokines (right panels). Data are representative of 5
mice. p < 0.01 for the percentage of live Myd88-/- P14 cells relative to WT P14 cells as
determined by scatter properties following 20hrs in culture.
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Figure 3.10. Myd88-/- and WT P14 cells do not exhibit differences in the expression of Bcl2family members following LCMV infection. Naïve Myd88-/- and congenic WT P14 cells were
cotransferred into WT recipients as in Figure 3.6. (A) Splenocytes were isolated at the indicated
time point post infection and the expression of Bcl-xL, Bcl-2 and Bim was determined on gated
Myd88-/- and WT P14 cells by intracellular staining. (C) Myd88-/- and WT P14 cells were
FACS-purified and pooled from 20 recipients 4 days post LCMV infection. RNA was purified
and the expression of the indicated Bcl2 family members was determined using an apoptosis PCR
microarray. Data represent mean + SD of two independent experiments.
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Figure 3.11. Myd88-/- and WT T cell are comparably sensitive to Fas and TNF-induced
apoptosis. Total T cells were MACS purified from the spleens and lymph nodes of naïve Myd88/- and CD45.1 congenic WT mice and co-cultured at a 1:1 ratio. Following primary activation by
plate-bound CD3 and soluble CD28 in the presence of IL-2, live cells were isolated and recultured under the indicated stimulation conditions. (A) After 24hrs, viability on gated Myd88-/and WT CD4 and CD8 T cells was assessed by the detection of Annexin V and total active
caspases. Data are representative of triplicate treatment groups in 2 independent experiments.
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Figure 3.12. MyD88 expression is not required for T cell responses to Type I IFNs. (A) WT
CD8 T cells were MACS purified from the spleens and LNs of naïve mice in the presence of
plate-bound aCD3 and soluble CpG and recombinant mouse IFN as indicated. After 48hrs, Bcl68

xL expression was determined by Western blotting. (B) CD8 T cells were MACS purified from
the spleens and LNs of naïve WT and Myd88-/- mice, cultured for 24 hours in the presence or
absence of plate-bound CD3 and then stimulated with recombinant mouse IFN for 30 minutes
as indicated. The expression of phospho-STAT 1 and phospho-STAT 3 was determined by
Western blotting. (C) CD8 T cells were MACS purified from the spleens and LNs of naïve
congenic WT and Myd88-/- mice and co-cultured at a 1:1 ratio under the indicated conditions.
Viability of gated WT and Myd88-/- cells was determined by scatter properties (top panels), or
cells were fixed and granzyme B expression on gated WT and Myd88-/- CD8 T cells was
compared following intracellular staining (lower panels). Data are representative of triplicate
treatment groups in 2 independent experiments. (D) Naïve congenic WT and Myd88-/- P14 cells
were transferred into WT recipients as in Figure 3.9. Splenocytes were isolated 4 days after
LCMV infection and viability of gated WT and Myd88-/- P14 cells was determined based on
scatter properties either directly ex vivo or following 20hrs of culture under the indicated
conditions. Data are representative of triplicate treatment groups in 2 independent experiments.
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Figure 3.13. Myd88-/- P14 cells express higher levels of lipid phosphotase genes and lower
levels of genes involved in calcium signaling and amino acid metabolism. Naïve Myd88-/- and
congenic WT P14 cells were cotransferred into WT recipients as in Figure 3.6. Myd88-/- and WT
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P14 cells were FACS-purified and pooled from 20 recipients 5 days post LCMV infection. RNA
was purified and the gene expression was determined by a full-genome Agilent microarray.
Differentially expressed genes with a fold change of 1.5 or greater were grouped into
functionally-related clusters using the NIH DAVID software. The 4 clusters with the highest
enrichment scores are shown. Data represent results from a single experiment in which pooled
RNA samples were divided to perform triplicate microarrays.
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CHAPTER 4: MyD88 is not required for the differentiation,
maintenance and reactivation of memory T cells following LCMV
infection

Introduction
The initial phase of rapid CD8 T cell expansion and differentiation into function effectors
during acute LCMV infection is followed by a period of contraction during which 9095% of T cells undergo apoptosis. The remaining LCMV-specific T cells persist as a
stable memory population. These memory T cells are maintained through slow
homeostatic turnover that is independent of antigen, and instead relies on signals from the
cytokines IL-7 and IL-15(Surh & Sprent 2008). Following subsequent encounter with the
same antigen, these memory T cells rapidly undergo expansion and differentiation into
secondary effectors. Recent work suggests that the costimulation through TNFR family
members plays an important role in maintaining the functional phenotype of memory T
cells(Allam et al. 2009). Thus, the signals involved in the regulation of the memory T cell
population are distinct from those involved in the regulation of naïve or effector cells.
Our results in Chapter 3 showed that MyD88 plays an intrinsic role in controlling
the survival and expansion of T cells during the initial phase of antigen-driven
proliferation following LCMV infection. As discussed earlier, it has been found that
MyD88-dependent signaling through direct TLR costimulation can promote T cell
differentiation into memory cells. Furthermore, memory T cells have been found to
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express higher TLR levels and possess greater sensitivity to stimulation with TLR
ligands. A recent study has shown that TLR2 ligands can act directly on memory CD8 T
in the absence of specific antigen to promote proliferation and cytokine
production(Cottalorda et al. 2009). These findings raise the possibility that MyD88dependent signals may play a role in regulating memory T cells generated in response to
LCMV infection. We therefore examined whether the defective expansion of LCMVspecific Myd88-/- T cells was also associated with additional defects in their contraction
and differentiation into memory cells.

4.1 Myd88-/- P14 cells generate a reduced frequency of memory cells following
LCMV infection
As we showed earlier, adoptively transferred Myd88-/- P14 cells expand considerably
less than WT P14 cells resulting in significantly fewer cells in the spleens of recipient
mice at the peak of the response, and also a similarly reduced number of memory cells 35
days post infection (Figs. 3.6 and 4.1A). While their initial expansion was reduced, serial
bleeds showed that Myd88-/- P14 cells contracted with comparable kinetics to WT P14
cells (Fig 4.1B).
The LCMV-specific effector T cell population contains considerable cellular
heterogeneity at the peak of the response. In particular, a small subset of effector T cells
expresses high levels of the IL-7R and low levels of killer cell lectin-like receptor G1
(KLRG1). In comparison to the majority of effector cells, which possess a
KLRG1highIL7Rlow phenotype, these KLRG1lowIL7Rhigh cells have a considerably
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greater potential of developing into long-lived memory cells. Thus, these
KLRG1lowIL7Rhigh cells have been termed memory precursor effector cells (MPECs),
while the KLRG1highIL7Rlow cells are primarily short lived effector cells (SLECs). We
found that the population of Myd88-/- P14 cells contained a comparable proportion of
SLECs and MPECs as WT P14 cells at the peak of the response, suggesting that the
Myd88-/- and WT effector T cell pools contained similar memory potential (Fig 4.1C).
Additionally, the majority of the Myd88-/- P14 cells that were present 35 days post
infection exhibited the KLRG1lowIL7Rhigh phenotype of memory cells.
Thus, while these data show that Myd88-/- CD8 T cells generate fewer memory
cells in response to acute LCMV infection, the phenotypic heterogeneity of the Myd88-/effector population, its kinetics of contraction and the similar relative proportions of
Myd88-/- and WT P14 cells at day 7 and day 35 post infection suggest that the reduced
number of Myd88-/- memory cells may simply reflect their reduced initial expansion.

4.2 T cells in Myd88T mice do not expand effectively in response to acute LCMV
infection
It is well established that the magnitude of the initial clonal burst significantly influences
the size of the memory T cell compartment(S. Hou et al. 1994). Therefore, in order to more
specifically examine whether MyD88 plays a role in the generation and maintenance of
memory cells, independent of its role in regulating primary T cell expansion, we needed a
system in which we could circumvent the defects associated with the absence of MyD88
during initial LCMV infection. To achieve this, we made use of recently developed mice
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in which the MyD88 gene has been floxed(B. Hou et al. 2008). While these mice had the
potential to allow us to conditionally delete MyD88 in memory T cells, we first wanted to
verify that deletion of MyD88 in naïve T cells using Myd88flox/flox mice produced results
consistent with our findings in Chapter 3 using germ-line Myd88-/- mice. We therefore
crossed Myd88flox/flox mice with mice expressing Cre recombinase under the CD4
promoter(Lee et al. 2001). In the resulting mice, which we will subsequently term
Myd88T mice, MyD88 expression is selectively deleted in all  T cells on the basis of
Cre expression starting at the CD4+CD8+ double-positive stage of thymocyte
development (Fig 4.2A).
We found greatly reduced CD8 T cell expansion in Myd88T mice in response to
LCMV infection, resulting in dramatically reduced numbers of CD44high CD8 T cells in
the spleens of infected Myd88T mice in comparison to Myd88flox/flox littermates that did
not express Cre-recombinase (p < 0.01) (Fig. 4.2B). Strikingly, CD8 T cell numbers in
Myd88T were reduced almost to the extent of complete Myd88-/- mice, supporting our
earlier results in Chapter 3 and suggesting that the contribution of MyD88 to T cell
expansion during LCMV infection is largely T cell intrinsic. Consistent with our earlier
findings, we found that the reduced number of CD44high CD8 T cells correlated with a
reduced frequency of LCMV-specific effector cells, as identified by tetramer staining, in
all tissues (p = 0.02) (Fig. 4.2C). Assessment of antigen-specific IFN production
following ex vivo restimulation with LCMV-derived peptides also supported the reduced
frequency of LCMV-specific effectors amongst both the CD8 and CD4 T cell populations
(p < 0.01) (Fig. 4.2D). Interestingly, ex vivo restimulation indicated a greater reduction
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in the frequency of cells responding to the np396-404 peptide than to the gp33-41 peptide
in MyD88T mice, as we had observed in Myd88-/- mice. Overall, these findings confirm
our earlier results, showing that MyD88 expression in T cells is critical for T cell
expansion in response to LCMV infection, and establish that inducible deletion of
MyD88 using Myd88flox/flox mice represents an appropriate model for examining the role
of MyD88 during LCMV infection.

4.3 A system to conditionally delete MyD88
To generate a system in which we could circumvent the defects associated with the
absence of MyD88 during initial LCMV infection we crossed Myd88flox/flox mice with
transgenic mice expressing CreERT2 under transcriptional control of the ubiquitin
promoter. To identify cells that underwent Cre-mediated deletion in these mice we
further crossed them with R26RYFP Cre reporter mice in which the activity of Cre
recombinase induces expression of YFP. To improve the efficiency of Cre-mediated
deletion of MyD88 we used experimental mice in which only a single allele of MyD88
needed to be deleted as the other was knocked out in the germline (Myd88flox/- R26RYFP
CreT2 mice, hereafter referred to as cKO). As controls we used mice in which one allele
of MyD88 was floxed and the other was WT (Myd88flox/+ R26RYFP CreT2, hereafter
referred to as cHet) (Fig. 4.3).
Having generated these mice we wanted to confirm that tamoxifen treatment
allowed the conditional deletion of MyD88 and that deleted cells could be identified on
the basis of YFP expression. We therefore examined the effect of tamoxifen treatment on
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the expression of MyD88 in splenocytes from cKO and cHet littermates. We found that
tamoxifen treatment induced high expression of YFP in 25-50% of splenocytes in both
cKO and cHet mice and that the proportion of YFP-expressing cells in the CD4 and CD8
T cell compartments was comparable to the proportion in the overall splenocyte
population (Fig 4.4A). In order to determine whether YFP served as an accurate reporter
of MyD88 expression, we sorted the YFP+ and YFP- fractions from tamoxifen treated
cKO and cHet mice or untreated controls and performed a western blot to assess MyD88
protein levels. We found that the majority of YFP+ splenocytes in cKO mice had deleted
MyD88 whereas there was minimal deletion in the YFP- compartment (Fig 4.4B). In
contrast, MyD88 expression was comparable in YFP+ and YFP- splenocytes from cHet
mice, suggesting that loss of a single Myd88 allele does not appreciably reduced MyD88
protein expression. While this showed that tamoxifen treatment effectively induced
MyD88 deletion in bulk YFP+ cKO splenocytes we also wanted to confirm that deletion
occurred specifically in the T cell compartment. We therefore sorted YFP+ and YFPCD4 and CD8 T cells from cKO mice and examined MyD88 expression by western blot.
Consistent with the overall splenocyte population, we found that MyD88 was largely
deleted in the YFP+ CD4 and CD8 T cells but was only minimally deleted in YFPpopulation (Fig 4.4C).
To further confirm that that YFP+ cells in cKO mice reproduce the phenotype that
we had observed in germline Myd88-/- T cells and Myd88T mice, we infected
tamoxifen-treated cKO and cHet mice with LCMV. As expected, we observed
significantly reduced expansion of the YFP+ CD8 T cells in cKO relative to cHet mice
following LCMV infection (p = 0.02) (Fig 4.5A). In contrast, we did not observe a
78

significant difference in the expansion of the YFP- CD8 T cells in cKO relative to cHet
mice (p = 0.27) (Fig 4.5B), supporting the limited deletion of MyD88 that we had
observed in YFP- cKO T cells (Fig 4.4C). In further support of our finding that YFP- and
YFP+ cells in cHet mice express comparable levels of MyD88 (Fig 3.3B) there was no
significant difference between the expansion of YFP+ and YFP- CD8 T cells in cHet
mice (p = 0.39), suggesting that heterozygous expression of MyD88 is sufficient to
regulate T cell expansion in response to LCMV infection. Consistent with our earlier
findings, the reduced CD8 T cell expansion in cKO mice correlated with a significantly
reduced percentage of LCMV-specific effector cells in the YFP+ (p < 0.02) (Fig 4.5C),
but not the YFP- CD8 T cell population (p > 0.74) (Fig 4.5D), as determined by antigenspecific IFN production. Furthermore, this reduced percentage of YFP+ IFN-producing
cells in cKO mice reflected a significantly reduced frequency of antigen-specific cells as
determined by tetramer staining (p = 0.02) (Fig. 4.5E).
Given that tamoxifen treatment of cKO presumably results in deletion of MyD88
in multiple immune compartments, the fact that we observe significant differences in the
expansion of YFP- and YFP+ T cell populations in cKO mice is consistent with our
earlier findings supporting a T cell-intrinsic role for MyD88. In addition, the finding that
there is no significant difference between the expansion of YFP- T cell population in
cKO and cHet mice supports our earlier mixed bone marrow chimera experiments (Fig.
3.5), which indicated that expression of MyD88 by half of the immune system is
sufficient to support T cell responses against LCMV. Overall, these results demonstrate
that tamoxifen treatment allows conditional deletion of MyD88 in cKO but not in cHet
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mice and that YFP expression serves as an accurate reporter for MyD88 expression in
cKO cells.

4.4 MyD88 is not required for T cell contraction and memory differentiation
following LCMV infection
Having shown that the YFP+ T cells in cKO and cHet and effectively replicate the
phenotype of germline Myd88-/- and Myd88+/- T cells following LCMV infection, we
used matched cKO and cHet control mice to examine whether MyD88 plays a role in the
contraction and differentiation of memory T cells independently of its role in initial
expansion (Fig 4.6A). Following infection with LCMV-Arm we found no significant
differences in the frequency of LCMV-specific CD8 T cells in the blood of cKO and
cHet mice 8 days following infection (p = 0.66) (Fig 4.6B), confirming that Myd88 is
haplo-sufficient for regulating initial T cell expansion We then treated mice with
tamoxifen on day 10 post infection to delete MyD88 after the peak of the CD8 T cell
response. Serial bleeds showed that tamoxifen treatment induced a comparable frequency
of YFP+ cells in the blood both cKO and cHet mice and that these cells were maintained
stably following infection (Fig 4.6C). This indicates that rejection of deleted cells on the
basis of their acquired expression of YFP is not a concern in this system.
We next examined the contraction and maintenance of LCMV-specific CD8 T
cells following deletion of MyD88 by measuring their frequency in peripheral blood.
Since we had found that MyD88 was only deleted effectively in the YFP+ population of
cKO mice (Fig 4.4 and 4.5) we limited our analysis to YFP+ T cells. We found that the
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populations of both gp33-specific (Fig 4.6D) and np396-specific (Fig. 4.6E) YFP+ CD8
T cells contracted with similar kinetics and were maintained at a comparable frequency in
the blood of cKO and cHet mice for up to 60 days post infection (p > 0.4 for all time
points).
One of the attributes that distinguishes memory T cells from naïve T cells is their
migration through peripheral tissues and bone marrow((Mackay et al. 1990)(Slifka et al.
1997). Since in vitro studies have suggested that TLR stimulation may influence the

expression of chemokines and integrins that regulate trafficking, we examined whether
the loss of MyD88 influenced the trafficking of memory T cells. We found a comparable
frequency of gp33-specific cells within the YFP+ lymphocyte population in the blood,
spleen, lymph nodes, liver and bone marrow of cKO and cHet mice 60 days after LCMV
infection (p > 0.72) (Fig 4.7A). This showed that the comparable frequency of LCMVspecific memory cells detected in the blood of cKO and cHet mice reflected a comparable
representation in other compartments, suggesting that MyD88 is not required for normal
homing and circulation of memory cells.
As discussed earlier, another attribute that distinguishes memory cells from naïve
T cells is that they do not require TCR-derived signals for their maintenance and instead
depend on the cytokines IL-7 and IL-15 for their homeostasis. It has recently been shown
that stimulation through MyD88-dependent TLR pathways can promote memory T cell
proliferation in response to IL-7(Cottalorda et al. 2009), raising the potential of decreased
IL-7 responsiveness in MyD88-deficient memory T cells. However, consistent with their
stable maintenance, we found that YFP+ LCMV-specific memory CD8 T cells in cKO
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mice expressed comparable levels of CD127, CD122 and CD25 to those in cHet mice,
suggesting normal recognition of these homeostatic cytokines (Fig 4.7B). In addition, we
also found that YFP+ LCMV-specific memory cells in both cKO and cHet mice
expressed a comparable distribution of CD62L, indicating that MyD88 is not required for
differentiation into effector memory or central memory subsets (Fig 4.7B). We also noted
that both cKO and cHet memory cells had downregulated PD-1 expression to the levels
of naïve cells (Fig 4.7 B), further supporting a memory cell phenotype rather than a
functionally exhausted phenotype. Overall, these findings indicate that, independent of its
role in regulating primary expansion, MyD88 is dispensable for the differentiation,
maintenance and migration of memory CD8 T cells following LCMV infection.

4.5 MyD88 is not required for memory T cell effector functions
As described earlier, another attribute of memory T cells is their ability to rapidly acquire
effector functions in response to stimulation. It has recently been shown that the
maintenance of memory T cells in a state of rapid responsiveness is dependent on the
provision of adequate costimulatory signals through members of the tumor necrosis
factor superfamily(Allam et al. 2009). Given that MyD88-dependent signals can serve as a
T cell costimulatory pathway and TLR ligands can directly promote IFN secretion from
memory T cells(Cottalorda et al. 2009), we examined whether the loss of MyD88
influenced the ability of cKO memory cells to rapidly produce effector cytokines.
60 days after LCMV infection, we found that a comparable frequency of YFP+
CD8 T cells in the splenocytes cKO and cHet mice produced IFNfollowing a brief
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restimulation with LCMV-derived peptides (p > 0.4) (Fig 4.8A). Effector cytokine
production was not limited to IFN since a comparable frequency of YFP+ CD8 T cells
in cKO and cHet mice also produced TNF and IL-2 following restimulation (Fig. 4.8A).
Furthermore, there was no significant difference in the overall distribution of memory
cells that produced various combinations of these cytokines (p > 0.2) (Fig. 4.8B),
suggesting that MyD88 is not required for the development of multifunctional memory
cells We also found a comparable frequency of IFN and IL-2 producing cells in the
YFP+ CD4 T cell compartment of cKO and cHet mice (p > 0.3) (Fig. 4.8A). These
results indicate that MyD88-dependent signals are not required for the rapid production
of effector cytokines by LCMV-specific memory T cells.

4.6 MyD88 is not required for memory T cell responses to secondary infection
Our results thus far indicate that T cell expression of MyD88 is required during initial
expansion following LCMV infection, but is dispensable for the subsequent
differentiation of functional memory cells. This raises the possibility that the MyD88dependent survival signals in effector T cells are triggered by ligands that are only
present during active LCMV infection, and that the lack of a role for MyD88 in memory
cells merely reflects that the relevant ligands are no longer present since virus has been
cleared. Alternatively, it is possible that, once naive cells have differentiated into LCMVspecific memory cells, signals through alternate pathways can compensate for the
absence of MyD88-dependent signals. To distinguish between these possibilities, we next
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examined whether MyD88 plays a role in controlling the survival and expansion of
memory cells following secondary infection with LCMV.
Using cKO and cHet mice that had been infected with LCMV-Arm 60 days
earlier and treated with tamoxifen following the primary response, we induced secondary
infection with a high dose of LCMV-CL13. Reinfection induced a rapid expansion of
CD8 T cells in both cKO and cHet mice. Notably, we observed a significantly lower
frequency of YFP+CD44+ CD8 T cells in the blood of cKO than cHet mice 3 days
following reinfection, however there was no longer a significant difference by day 6 (Fig
4.9A). Surprisingly, we detected minimal expansion of the gp33-specific population in
the blood of either cKO or cHet mice, but did find robust expansion of the np396-specific
population (Fig. 4.9B), which has been reported to dominate secondary responses(Tebo et
al. 2005). Consistent with the pattern in overall CD44+ cells, there was a significantly

lower frequency of YFP+ np396-specific cells in the blood of cKO mice 3 days post
reinfection, but both cKO and cHet mice contained a comparable frequency by 6 days
post reinfection. This was mirrored by a comparable frequency of LCMV-specific CD8 T
cells in the spleens of cKO and cHet mice 6 days post infection (p = 0.30) (Fig. 4.9C).
Since we had observed increased apoptosis in Myd88-/- effector cells during
primary expansion in response to LCMV, we examined the survival of LCMV-specific T
cells following secondary expansion. Consistent with their comparable expansion, we
found no notable differences in the apoptosis of YFP+ np396-specific cells in cKO and
cHet mice either directly ex vivo, or following in vitro culture (Fig. 4.9D).
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While these data suggested effective expansion and survival of MyD88-deficient
memory T cells, it was possible that the secondary T cell response observed in cKO mice
was due to the outgrowth of a population of YFP+ CD8 T cells that had failed to delete
MyD88. We therefore sorted the YFP+ and YFP- fractions from the CD44+CD8 T cell
populations in cKO and cHet mice and examined MyD88 expression. We found that the
majority of YFP+ cells in cKO mice still lacked MyD88 expression, indicating that the
memory T cell response in cKO mice did not merely reflect preferential expansion of
MyD88-sufficient cells (Fig 4.9E). It should also be noted that some of the MyD88
expression in the YFP+ cKO sample may represent contaminating YFP- cells since the
sort purity of this sample was only 80%.
We also considered whether MyD88 may potentially be involved in the
differentiation of memory cells into functional secondary effectors. Ex vivo restimulation
with LCMV-derived peptides indicated a comparable frequency of IFN producing cells
within the YFP+ CD8 T cell compartments of cKO and cHet mice (4.10A), as well as a
similar frequency and distribution of cells that produced combinations of IFN, TNF
and IL-2 (p > 0.1) (4.10B). Interestingly, in contrast to our results using gp33 tetramers,
we found that secondary LCMV infection induced a considerable expansion in the
population of cells that produced IFN in response to restimulation gp33-41 in both cKO
and cHet mice. This could indicate preferential expansion of cells recognizing the epitope
in the context of H2-Kb during the secondary immune response to LCMV. Overall, these
data indicate that, while MyD88-expression may contribute slightly to the kinetics of
early memory T cell expansion following secondary LCMV infection, the MyD8885

dependent signals induced by LCMV infection are not critical for memory T cells to
achieve maximal expansion or differentiation at the peak of the secondary response.

Summary
It is well established that memory T cells are functionally and phenotypically distinct
from naïve and effector T cells. For example, memory T cells rely on the cytokines IL-7
and IL-15, rather than TCR-induced signals for their homeostasis and concordantly
express higher levels of the IL-7R and IL-15R than naïve T cells. Studies have also found
that memory T cells constitutively expresses higher levels of TLRs and are more
responsive to TLR ligands than naïve T cells, thus raising the possibility that MyD88dependent pathways may play a more important role in regulating memory T cell
responses. However, our results in this chapter indicate that, following the primary
response to acute LCMV infection, LCMV-specific T cells do not require MyD88dependent signals to support their differentiation into memory cells or their subsequent
maintenance. Furthermore, in contrast to the critical requirement for MyD88 in
supporting naïve T cell expansion in response to primary LCMV infection, memory T
cells expand and differentiate effectively following secondary encounter with LCMV in
the absence of MyD88. Thus, differential requirements for MyD88-dependent signaling
appear to represent another attribute that functionally distinguishes memory T cells from
naïve T cells.
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Figure 4.1. Myd88-/- P14 cells generate fewer memory cells following LCMV
infection. Myd88-/- or WT P14 cells were transferred into individual WT recipients, which were
infected 18hrs later. (A) On day 7 and day 35 post infection the numbers of WT and Myd88-/P14 cells per spleen were enumerated. Data represent mean + S.D of 9 mice and p < 0.01 for both
time points. (B) LCMV-infected recipients were longitudinally bled and the percentage of WT
and Myd88-/- P14 cells was determined relative to total CD8 T cells. Data represent mean +/- SD
of at least 9 mice and p < 0.01 for all time points. (E) Expression of KLRG-1 and IL-7R by WT
and Myd88-/- P14 cells in day 7 and day 35 infected spleens. Data are representative of 5 mice
and differences were not statistically significant.
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Figure 4.2. Myd88T mice mount greatly reduced T cell responses to LCMV infection. (A) T
and B cells were FACS purified from the spleen of a Myd88T mouse and MyD88 expression
was examined by Western blot. (B-D) Myd88flox/flox, Myd88T and Myd88-/- mice were
examined 8 days after LCMV infection. (B) The number of splenic CD8 T cells was determined.
Data represent mean + SD of 4 mice per group. (C) The frequency of tetramer-specific cells
amongst gated CD8 T cells from the indicated tissues was measured. (D) Splenocytes were
restimulated with the indicated peptides and antigen-specific IFN production was assessed.
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Figure 4.3. Schematic of the predicted outcome of tamoxifen treatment in cKO and
cHet mice
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Figure 4.4. Tamoxifen treatment allows deletion of MyD88 correlated with YFP expression
in cKO mice. (A) cHet mice cKO mice were treated with tamoxifen or left untreated and YFP
expression in the indicated splenocyte populations was determined 5 days later. (B) YFP+ and
YFP- splenocytes were FACS-purified from treated or untreated cHet and cKO mice. MyD88
expression was determined by Western blot. (C) YFP+ and YFP- CD4 and CD8 T cells were
FACS-purified from treated or untreated cKO mice and MyD88 expression was determined by
Western blot.
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Figure 4.5. YFP+ T cells in cKO mice exhibit reduced expansion in response to LCMV
infection. cKO and cHet mice were treated with tamoxifen and infected with LCMV-Arm 5 days
later. Splenocytes were examined 8 days after infection. (A-B) The frequency of CD8 T cells in
the YFP+ (A) and YFP- (B) splenocyte populations was determined. (C-D) Splenocytes were
restimulated with the indicated peptides and the frequency of IFN-producing YFP+ (C) and
YFP- (D) CD8 T cells was determined by intracellular staining. (E) The frequency of LCMVspecific YFP+ CD8 T cells was determined using tetramers. All graphs represent mean + SD of at
least 4 mice.
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Figure 4.6. MyD88 is not required for the development and maintenance of memory T cells
following LCMV infection. (A) Experimental design. (B) The frequency of tetramer-specific
CD8 T cells in the blood of cKO and cHet mice was determined 8 days after LCMV infection.
Data represent mean + SD of at least 6 mice. (C) The frequency of YFP+ cells was measured in
blood lymphocytes of cKO and cHet mice by serial bleeds. Data represent mean +/- SD of at least
6 mice. (D-E) The frequency of gp33-specific (D) and np396-specific (E) cells within YFP+
blood lymphocytes of cKO and cHet mice was determined by tetramer staining. Data represent
mean +/- SD of at least 6 mice.
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Figure 4.7. MyD88 is not required for normal T cell tissue homing or the acquisition of a
memory phenotype following LCMV infection. cKO and cHet mice were infected with
LCMV-Arm and treated as in Figure 4.6 (A) The frequency of gp33-specific cells within the
YFP+ CD8 T cells from the indicated tissues of cKO and cHet mice was assessed by tetramer
staining 60 days after infection. (B) The expression of the indicated phenotypic markers was
determined on gated gp33-specific YFP+ cells from the spleens of cKO and cHet mice 60 days
after infection.
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Figure 4.8. MyD88 is not required for the rapid production of effector cytokines by memory
T cells. (A) Splenocytes from cKO and cHet mice 60 days following LCMV infection were
restimulated with the indicated LCMV-derived peptides and IFN, TNF and IL-2 production by
YFP+ CD8 T cells was assessed by intracellular staining. (B) The frequency of YFP+ CD8 T
cells producing the indicated combinations of cytokines in response to stimulation with pooled
LCMV peptide was determined. Data represent mean + SD of 3 mice.
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Figure 4.9. MyD88 is not critical for memory T cell expansion in response to secondary
LCMV infection. cKO and cHet mice were infected with LCMV-Arm and treated as in Figure
4.6, and were reinfected with LCMV-CL13 60 days after primary infection. (A-B) The frequency
of CD44+ (A) and np396-specific (B) YFP+ CD8 T cells in the blood at the indicated time points
was determined by tetramer staining. Data show mean +/- SD of 3 mice. (C) The frequency of
tetramer specific YFP+ CD8 T cells in the spleens of cKO and cHet mice was assessed 6 days
post reinfection. (D) YFP+ and YFP- CD44+CD8 T cells were sorted from the spleens of
reinfected cKO and cHet mice and MyD88 expression was measured by Western blot. (D) The
viability of gated np396-specific YFP+ CD8 T cells from cKO and cHet mice was assessed by
Annexin V staining direct either ex vivo or after the indicated 20 hours of in vitro culture as
indicated. Data are representative of 3 mice per group.
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Figure 4.10. MyD88 is not required for the differentiation of memory T cells into secondary
effectors. LCMV immune cKO and cHet mice were reinfected with LCMV Cl-13 as in Figure
4.9. (A) 6 days after reinfection, splenocytes were restimulated with the indicated LCMV-derived
peptides and IFN, TNF and IL-2 production by YFP+ CD8 T cells was assessed by
intracellular staining. (B) The frequency of YFP+ CD8 T cells producing the indicated
combinations of cytokines in response to stimulation with pooled LCMV peptide was determined.
Data represent mean +SD of 3 mice per group.

96

CHAPTER 5: Discussion and Speculation
Defining the role of MyD88 in T cells: contrasting the findings of in vitro and in vivo
studies
A growing number of studies have recently shown that TLR ligands can act directly on
mouse and human T cells to promote their proliferation, survival and differentiation in
vitro, challenging the prevailing view that suggested that the importance of TLRs was
restricted to cells of the innate immune system. These findings raised the potential that
the defective T cell responses against numerous pathogens that had been observed in
MyD88 mice may reflect a direct role for MyD88-dependent signaling in T cells.
However, the relative contributions of T cell extrinsic and intrinsic MyD88-dependent
signals and, thus, the overall physiological relevance of MyD88-expression in T cells,
during a natural in vivo immune response remained unclear.
The findings presented in this dissertation being to address these issues by using
LCMV infection as model viral pathogen to examine the role of MyD88 during in vivo T
cell responses. We confirm that MyD88 plays an important T cell-extrinsic role in regulating T
cell responses, as evidenced by reduced expansion and a shift in immunodominance during the
response of WT CD8 T cells to LCMV infection in a Myd88-/- host (Chapter 3.3). This supports
the reduced production of type I IFNs and other pro-inflammatory cytokines by Myd88-/APCs(Zhou et al. 2005)(Jung et al. 2008), which, in turn, have been shown to be important in
regulating T cell expansion(Kolumam et al. 2005)(Aichele et al. 2006). However, our findings
importantly show that MyD88 also plays a critical, T cell-intrinsic role in supporting the survival
and accumulation of antigen specific CD8 T cells during the response to acute LCMV infection.
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During the course of this dissertation work, a number of other studies have
expanded upon earlier in vitro work to examine the potential role of TLR and MyD88dependent signaling in T cells during in vivo immune responses. As discussed earlier,
Myd88-/- mice display significantly greater mortality following infection by the
protozoan pathogen, Toxoplasma gondii(Scanga et al. 2002). This increased susceptibility
is associated with reduced Th1 effector responses, which have been attributed to
defective innate immune activation and reduced levels of IL-12 production in these mice.
In a recent study, our lab found that mixed bone marrow chimeras in which MyD88deficiency was largely restricted to the T cell compartment generated reduced numbers of
IFN-producing effector T cells following T. gondii infection and were highly susceptible
to toxoplasmic encephalitis, succumbing to infection with similar kinetics to full Myd88/- mice(LaRosa et al. 2008). These findings indicate that MyD88 expression in T cells is
required for prolonged resistance to T. gondii in the setting of an intact innate immune
response but did not establish a mechanism by which MyD88 contributes to T cell
responses in this model.
MyD88 expression in T cells was also found to play a role in CD4 T cellmediated colitis. When CD4+CD45RBhigh T cells are transferred into RAG1/2-deficient
animals, the recipients rapidly develop wasting disease associated with clinical signs of
colitis(Powrie et al. 1993)(Morrissey et al. 1993). This experimental colitis depends on the
presence of commensal intestinal microflora and TLRs from these microorganisms are
thought to activate innate immune cells in the gut and thereby indirectly support
colitogenic T cell responses(Cong et al. 1998)(Sartor 2001). However, it has recently been
98

reported that purified MyD88-/- CD4+CD45RBhigh T cells transferred into RAG-deficient
recipients do not induce as severe colitis as WT T cells(Tomita et al. 2008)(Fukata et al.
2008). Using competitive transfer systems, Myd88-/- colitogenic CD4 T cells were shown

expand less effectively than WT cells and this correlated with reduced production of
effector cytokines. In particular, MyD88-/- CD4 T cells isolated from the lamina propria
produced significantly less IL-17. Furthermore, it was shown that Myd88-/- CD4 T cells
did not effectively differentiate into IL-17-producing cells in vitro, suggesting that
MyD88 may play a role in Th17 polarization(Fukata et al. 2008). Relevant to this, Myd88/- mice are highly resistant to the induction of experimental autoimmune encephalitis
(EAE), which is an IL-17 mediated autoimmune disease(Marta et al. 2008). While reduced
numbers of Myd88-/- Th17 cells in this model have been attributed to decreased
production of IL-6 and IL-23 by Myd88-/- dendritic cells, it is interesting to consider
whether they also reflect a T cell-intrinsic role for MyD88 in supporting Th17 responses.
These studies using T. gondii and colitis models demonstrated that MyD88dependent signals in T cells are a physiologically relevant component of T cell responses
in vivo. However, since they were only able to examine overall polyclonal T cell
responses, these studies were limited in their ability to directly compare antigen-specific
populations of WT and MyD88-/- effector T cells. Thus, while reduced levels of CFSE
dilution and BrdU uptake were identified in MyD88-/- colitogenic CD4 T cell
populations, it remained unclear whether this represented reduced proliferation of
antigen-specific T cell clones or increased cell death resulting in a smaller proportion of
dividing colitogenic cells. Similarly, it was unclear whether impaired cytokine production
by MyD88-/- T cell populations in these models represented impaired effector
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differentiation, reduced cytokine secretion by antigen-specific responders, or a relatively
smaller proportion of cytokine-producing effector cells.
The findings presented in this dissertation support and expand upon these studies
to further define the role of MyD88 in T cells during viral infection. The use of LCMV as
an infection model allowed us to employ epitope-specific cytokine production, MHC
Class I tetramers and P14 TCR-transgenic mice to directly compare the responses of WT
and MyD88-deficient antigen-specific T cells. Our results in Chapter 3, using adoptive
cells transfers and bone marrow chimeras, clearly demonstrate that MyD88 plays a T
cell-intrinsic role in supporting T cell expansion, but not effector differentiation, in
response to LCMV infection. While this reduced expansion is associated with decreased
BrdU incorporation in the overall Myd88-/- CD8 T cell population, examination of
LCMV-specific effector cells allow us to attribute the reduced expansion to impaired
survival rather than impaired proliferation. Interestingly, examination of the polyclonal T
cell response indicated the absence of MyD88 resulted in a more severe reduction in
np396-specific than gp33-specific T cells. This may relate to the fact that T cells
responding to the np396 epitope express higher levels of PD-1 and have been found to be
in a more apoptotic state than those responding to gp33 epitope(X. Z. Wang et al. 2004), and
may thus be more dependent on MyD88-dependent signals to rescue them from
apoptosis.
Thus, while in vitro studies have suggested that MyD88-depndent TLR signals
can potentially regulate CD8 T cell proliferation, survival and effector
differentiation(Cottalorda et al. 2006), our results in Chapter 3 indicate that naïve CD8 T
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cells can be activated and induced to proliferate and differentiate into functional and phenotypic
effector cells during the early stages of the response to LCMV in the absence of MyD88. Instead
the importance of MyD88 is limited to a critical role in supporting their subsequent survival and
sustained accumulation, thereby controlling the ultimate size of the T cell effector

population at the peak of the response (Fig. 5.1). Thus, MyD88-dependent signals appear
to act in an analogous fashion to inflammatory cytokines, which serve as a third signal, in
addition to TCR and costimulatory receptor engagement, in promoting optimal T cell
expansion(Curtsinger et al. 2005). Our results are supported by recent studies that also
indicate a similar role MyD88 in antigen-specific T cells during responses to LCMV and
vaccinia virus infection(Bartholdy et al. 2009)(Quigley et al. 2009)(Zhao et al. 2009). This
suggests that the defects associated with Myd88-/- T cells in the T. gondii and colitis
models may also primarily be explained by reduced effector cell survival rather than
impairments in proliferation or effector cell differentiation, though it is difficult to
extrapolate findings between these experimental systems since the precise nature of the
MyD88-mediated signals may vary.
In vitro studies have also suggested that MyD88-dependent TLR signals may
contribute to the differentiation, homeostasis and reactivation of memory T cells(Mercier
et al. 2009)(Cottalorda et al. 2009). We find that MyD88 expression in T cells is important

in regulating the size of the resulting memory population following LCMV infection and
a similar finding has been reported following vaccinia virus infection(Quigley et al. 2009).
However, this likely reflects an indirect result of the importance of MyD88 in supporting
initial T cell expansion, since initial antigen encounter and the number of effector cells
generated during the primary response are known to regulate the differentiation and
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ultimate size of the memory population(Hou et al. 1994)(Shaulov & Murali-Krishna 2008).
Indeed, our results in Chapter 4 indicate that, independent of its role in the initial phase of
T cell expansion, MyD88-expression is not required for the subsequent differentiation
and maintenance of functional memory T cells. Furthermore, memory T cells appear to
be less dependent on MyD88-dependent signals than naïve T cells for their expansion in
response to secondary LCMV infection. Similarly, memory T cells induced in Myd88-/mice by vaccination with gp33-expressing adenovirus were also shown to expand
effectively in response to LCMV infection(Bartholdy et al. 2009). Thus, while in vitro
studies suggest a role for MyD88-dependent signals in regulating memory T cell
homeostasis and responses, it appears this these signals are not critical during in vivo
responses to LCMV infection.

A consideration of the potential mechanisms for MyD88-mediated T cell survival
during infection
Perhaps the most notable difference between our results and those suggested by in
vitro studies is that the role of MyD88 during LCMV infection does not appear to be
attributable to a specific TLR pathway. While TLR2 and TLR9 are the only MyD88dependent TLR pathways that have been found to stimulate mouse CD8 T cells in vitro,
neither Tlr2-/- nor Tlr9-/- mice recapitulated the impaired T cell expansion observed in
Myd88-/- mice following LCMV infection. Indeed, Tlr2-/- mice exhibited significantly
increased numbers of LCMV-specific cells in their spleens at the peak of infection. This
surprising finding could potentially be related to the reduced frequency of Tregs reported
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in these mice(Netea et al. 2004) or to reduced recruitment of T cells into other tissues due
to impaired chemokine production(Zhou et al. 2008). It has been shown that mice deficient
in TLR3, TLR4, and TLR8 mount normal CD8 T cell responses to LCMV, and while
LCMV-specific CTL numbers are slightly reduced in mice lacking both TLR7 and TLR9,
they do not recapitulate the phenotype of Myd88-/- mice (Jung et al. 2008).
MyD88 is also involved in signaling downstream of the IL-1R and IL-18R, and
these cytokines have been shown to play a role in promoting CD8 T cell survival(Wen Li
et al. 2007). However, we found no reduction in LCMV-specific CD8 T cells in the

spleens of IL1r1-/- mice and somewhat reduced numbers in IL18r1-/- mice, which still
greatly exceeded those found in Myd88-/- mice, suggesting that these pathways also do
not account for the importance of MyD88 during LCMV infection. IL-33, which signals
through ST2, has also recently been described as another IL-1R family cytokine. IL-33
signaling has been implicated in the polarization of TH2 CD4 T cells(Schmitz et al. 2005),
but has not been described to play a role in CD8 T cells. While this suggests that IL-33 is
unlikely to account for the impaired responses of Myd88-/- CD8 T cells, its potential role
cannot yet be ruled out.
Thus, while MyD88 clearly plays an important role in T cells during responses to
LCMV infection, the specific upstream initiators of MyD88-mediated signaling remain
unclear. Similarly, the T cell impairments associated with MyD88-deficiency during T.
gondii infection cannot be attributed to a role for individual TLRs or IL-1 and
IL18(Scanga et al. 2002)(Debierre-Grockiego et al. 2007)(Hitziger et al. 2005)(Yarovinsky et al.
2005)(LaRosa et al. 2008). In addition, while the role of MyD88 in vaccinia virus specific T
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cells has been attributed to TLR2 signaling in one study(Quigley et al. 2009), another was
unable to find such an association(Zhao et al. 2009). This suggests that an inability to
define a role for specific TLR/cytokine pathways may be a consistent feature when
considering the importance of MyD88 in T cells during in vivo immune responses. One
possible explanation for this is that there is considerable redundancy and cooperation
between different MyD88-dependent pathways in vivo, as has been noted in certain
infections (Sørensen et al. 2008). Another, non-mutually exclusive, possibility is that the
importance of MyD88 in CD8 T cells during infection is linked to novel upstream
receptors or a function outside of its traditional role in TLR signaling.
In support of this latter possibility, while TLR-induced survival of T cells is
associated with clear upregulation of Bcl-xL expression in vitro(Cottalorda et al. 2006), we
did not detect significant differences in the levels of this pro-survival factor between WT
and Myd88-/- CD8 T cells following LCMV infection. Instead the results of a full
genome microarray suggested that the reduced survival of Myd88-/- cells may be related
to differences in the expression of genes related to inositol phosphate metabolism,
calcium signaling and amino acid metabolism. Though the significance of these findings
is somewhat unclear, it is interesting to note that a potential connection between MyD88dependent signaling pathways and regulation of cellular metabolism is suggested by a
recent study that found that TRAF6-deficient CD8 T cells exhibit alteration of genes
regulating fatty acid metabolism following Listeria monocytogenes infection(Pearce et al.
2009).
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In considering other potential roles for MyD88 outside of TLR signaling we noted
that MyD88 has been found to associate with the Fas-related signaling molecule, FADD
in fibroblasts and macrophages. As a result of homotypic death-domain interactions,
expression of FADD can inhibit signaling through TLRs by sequestering MyD88 away
from TLR signaling pathways(Zhande et al. 2007). This raised the reciprocal possibility
that loss of MyD88 may allow excess FADD to be recruited to the Fas signaling pathway,
thereby rendering Myd88-/- T cell hyper-responsive to Fas induced apoptosis. However,
we did not find that Myd88-/- T cells had increased sensitivity of Fas or TNF induced
AICD in vitro, suggesting that these pathways do not account for the reduced survival of
Myd88-/- T cells following LCMV infection. However, an interaction of MyD88 with
other death-domain containing proteins remains a possibility.
It is also interesting to note the striking similarity in the apparent roles of Type I
IFN and MyD88-dependent signals in T cells during LCMV infection. Like Myd88-/- T
cells, IFN-IR-/- T cells proliferate and differentiate but exhibit reduced survival, resulting
in dramatically reduced expansion following LCMV infection(Aichele et al.
2006)(Kolumam et al. 2005). While this similarity in phenotype may be coincidental, it is

tempting to speculate that it may reflect an intersection between the IFN-IR and MyD88
signaling pathways. As discussed earlier, MyD88 is known to play an important role in
promoting the production of Type I IFNs through the induction of IRF-dependent
signaling pathways(Taro Kawai et al. 2004). However, a potential role for MyD88
downstream of Type I IFN induced signaling pathways is less clear. TLR signaling has
been shown to promote STAT1 phosphorylation in macrophages, raising the potential
that MyD88 may be involved in STAT-dependent cytokine responses(Rhee et al. 2003).
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However, given that TLR signaling has been shown induce the production of IFN in
APCs, this finding may reflect a secondary outcome of increased IFN production. In
support of this, we did not observe defects in STAT phosphorylation or general responses
to Type I IFNs in Myd88-/- CD8 T cells, though this does not rule out a more subtle role
for Type I IFNs in promoting MyD88-dependent signals or vice versa.
Notably, similarly to IFN-IR-/- CD8 T cells, IFNR1-/- CD8 T cells have also
been shown to exhibit reduced expansion in response to LCMV infection(Whitmire et al.
2005), though the mechanisms by which IFN directly promotes CD8 T cell abundance

remain unclear. Interestingly, MyD88 has been shown to physically interact with the
IFNR1 and thereby stabilize IFN-induced mRNA transcripts in macrophages(Sun & Ding
2006). This raises the intriguing possibility that MyD88 may function similarly in CD8 T

cells, suggesting that the reduced survival of Myd88-/- CD8 T cells following LCMV
infection reflects impaired expression of IFN-induced survival genes. Furthermore, a
similar association between MyD88 and the IFN-IR remains an unexplored possibility.
In considering the role of Type I IFNs in regulating T cell responses, it is notable
that T cells appear to be particularly dependent on IFN-IR-mediated signals for their
clonal expansion in the setting of LCMV infection. In contrast, T cell expansion in
response to vaccinia, VSV and Listeria monocytogenes infection is only mildly impaired
in the absence of IFN-IR signaling(Thompson et al. 2006). Correspondingly, while
MyD88-dependent signals are critical for T cell survival in the setting of LCMV and
vaccinia infection(Quigley et al. 2009)(Zhao et al. 2009), it is interesting to note that there is
no significant reduction in the expansion of Myd88-/- T in response to VSV(Bartholdy et
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al. 2009) and only moderately impaired expansion in response to adenovirus(Bartholdy et
al. 2009) and Listeria infection (S. M. Kaech, unpublished observations). Furthermore,

while we have found that MyD88-expression in T cell is required for resistance to T.
gondii(LaRosa et al. 2008), it is notable that loss of MyD88 results in a far smaller
reduction in effector CD8 T cell frequency during T. gondii infection than LCMV
infection.
Thus, it appears that MyD88-dependent signals are not universally required for
promoting T cell expansion and their importance is instead linked to certain infections.
This could indicate that the upstream ligands that trigger the relevant MyD88-dependent
pathways in T cells are only encoded by, or induced in the setting of, certain pathogens.
Alternatively, and non-exclusively, it is possible that other characteristics of the infection
dictate the relative importance of MyD88-dependent signals in contributing to overall T
cell survival. Due to its non-cytopathic nature, LCMV provides a very large antigenic
load, which is an important contribution to the dramatic T cell expansion induced by this
virus (Thompson et al. 2006). In addition, studies using different strains of LCMV indicate
that the Myd88-/- T cell response is more significantly impaired following infection highdose with the invasive LCMV-Traub strain than the acute LCMV-Arm strain(Bartholdy et
al. 2009). This could indicate that an environment of prolonged antigenic load is an

important factor in determining the importance of MyD88-dependent survival signals.
Consequently, the more severe impairment in the np396-specific responses may be
related to higher antigen loads of this immunodominant epitope(van der Most et al. 2003).
This could also suggest that the relatively minor role for MyD88-expression in memory T
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cell expansion following secondary LCMV infection is related to the relatively rapid
clearance of virus. To further explore this possibility we are interested in examining the
role of MyD88-dependent signals in regulating T cell survival and maintenance in the
setting of persistent antigen exposure induced during chronic LCMV infection(Wherry et
al. 2003).

While this potential avenue of investigation would serve to further define the role
of MyD88 in T cells during infection, additional insight would be gained by identifying
the critical upstream and downstream mediators that are responsible for conferring the
ability of MyD88 to promote T cell survival during LCMV infection. As discussed
earlier, MyD88 is known to engage upstream receptors through homotypic TIR domain
interactions and subsequently recruit IRAK4 through homotypic death domain
interactions ultimately leading to NFB activation(Wesche et al. 1997)(Martin & Wesche
2002). However, additional studies have found that MyD88 is also able to activate the Akt

pathway through a direct interaction of phosphatidylinositol 3-kinase (PI-3-K) with a
tyrosine motif in the MyD88 TIR domain(Li et al. 2003)(Rhee et al. 2006)(Gelman et al.
2006). At present it is unclear which, if any, of these pathways is responsible for the

MyD88-induced survival effect during LCMV infection.
The fact that TLR stimulation can promote Akt phosphorylation in vitro, and that
Akt signaling is required for T cell responses to vaccinia has led others to conclude that
Akt activation represents the critical MyD88-dependent pathway during infection, though
this has not been directly demonstrated(Quigley et al. 2009). Indeed, we have found that the
Akt pathway primarily contributes to TLR-induced T cell proliferation rather than
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survival(Gelman et al. 2006), which is inconsistent with our finding that Myd88-/- T cells
have a specific defect in survival rather than proliferation. Furthermore, the fact that mice
lacking IRAK4, the signaling kinase downstream of MyD88, also exhibit reduced T cell
expansion in response to LCMV(Lye et al. 2008) suggests that this may represent the
relevant pathway during LCMV infection. However, this hypothesis is complicated by
the finding that T cells lacking TRAF6, the signaling molecule downstream of IRAK4,
do not exhibit impaired expansion but rather impaired memory differentiation following
Listeria infection(Pearce et al. 2009), contrasting with the phenotype of Myd88-/- T cells.
In addition, since Bcl-xL expression is upregulated as a result of MyD88-induced NF-B
activation, the fact that we did not observe differences in the expression of Bcl-2 family
members further questions the role of this pathway in regulating T cell survival during
LCMV infection.
In considering how to clarify some of these issues, it is useful to note that studies
have begun to identify the molecular motifs associated with MyD88 TIR and Death
domain interactions(Ohnishi et al. 2009)(Chunsheng Li et al. 2005)(Loiarro et al. 2009)(Gelman
et al. 2006). It is therefore potentially feasible to generate mutated forms of MyD88 that

are unable to initiate specific signaling pathways. By transfecting Myd88-/- deficient cells
with mutant forms of MyD88, the relative importance of various domains of MyD88 in
promoting T cell survival during LCMV infection could be selectively assessed. This
approach could help to clarify the critical binding partners of MyD88 and elucidate the
relevant signaling pathways, thereby establishing a more comprehensive mechanism for
the physiological role of MyD88 in T cells.
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Conclusions
MyD88-dependent signaling through TLRs has long been recognized to play
an important, indirect role in supporting T cell responses through myriad effects on innate
immune cells, including up-regulating antigen presentation, co-stimulatory molecule
expression and inflammatory cytokine production. In addition to these importance effects
in cells of the innate immune system, it is now clear that MyD88-dependent TLR ligands
can also directly on T cells. Several in vitro studies have shown that TLRs can potentially
serve as co-stimulatory receptors on T cells, and that their engagement supports TCRmediated signals, promoting effector responses including enhanced cytokine production,
proliferation and survival. This dissertation builds on this work to clearly demonstrate
that MyD88-dependent signals in T cells play a critical role in supporting in vivo T cellresponses against a viral pathogen. While MyD88 expression in T cells during LCMV
infection appears to be dispensable for initial activation, proliferation, and differentiation
into fate committed subsets of effectors, it is required for the survival and accumulation
of effector T cells during the phase of antigen driven proliferation. These findings suggest
a model (Figure 5.1) in which MyD88 plays an important, indirect role in promoting
initial T cell activation through APCs in the lymph nodes but also acts directly in effector
T cells at the site of infection, to provide signals that support the survival and clonal
expansion. Thus MyD88 may serve as link that allows T cells to directly respond to
inflammatory stimuli that deliver pro-survival signals during viral infection. At this point,
the nature of the inflammatory stimuli that link MyD88 to T cell survival remain unclear
and raises the possibility that the importance of MyD88 may be related to functions
outside of it traditional role in TLR signaling during LCMV infection. Overall, by
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broadening the importance of MyD88 in T cells, our findings support a shift in the dogma
that restricts the role MyD88 to cells of the innate immune system and may have
significant implications for understanding the signals that control T cell survival during
inflammatory immune responses.
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Figure 5.1. Model for the direct and indirect contributions of MyD88 to T cell responses
during infection.
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